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Abstract
Plants lignans are ubiquitous compounds in plants, and some of them, such as
matairesinol and secoisolariciresinol, are converted into the mammalian lignans
enterolactone and enterodiol by gut microflora. Lignans have been suggested to
decrease risks of hormone-related cancers in man and to retard tumorigenesis in
animal models of cancer. Diet has a major impact on the incidence of colorectal
cancer, and lignans have been proposed to prevent this form of cancer. Multiple
intestinal neoplasia (Min) mice, which have an inherited mutation in the adenomatous
polyposis coli gene, and thus, a spontaneous formation of intestinal adenomas, serve
as a useful experimental model in studies of diet and colon cancer.
The  aims  of  this  study  were  to  elucidate  the  role  of  lignan  sources  and  lignan
metabolism in adenoma formation in Min mice, and to see if there is gender or
genotype based differences in these parameters. To study this, the mice were fed
lignan-rich foods, such as flaxseed and rye bran, and the pure lignans 7-
hydroxymatairesinol, matairesinol and secoisolariciresinol in aglycone forms.
Furthermore, the role of other dietary components in flaxseed and rye bran (besides
lignans) in tumour formation, and the effects of diets on levels of such cell-signalling
parameters as b-catenin, cyclooxygenase-2 and protein kinase C-z were  also
elucidated.
The results showed that flaxseed and rye diets providing such lignans as
secoisolariciresinol diglycoside and syringaresinol showed no clear anticarcinogenic
effects in Min mice. Studies with the three pure lignans yielded conflicting results; the
crude extract of 7-hydroxymatairesinol was chemopreventive, pure matairesinol had
tumour growth-favouring effects, and pure secoisolariciresinol had a neutral effect.
The exact mechanism of action of these lignans was unclear, but it did not appear to
depend on enterolactone formation. We found also that neither plasma enterolactone
nor the intestinal enterodiol, enterolactone or secoisolariciresinol had
6chemopreventive effects on adenoma formation in male and female Min mice.
Furthermore, we found gender-based differences in the gut enterolactone metabolism
and the number of colon tumours. The results suggested also that other dietary
components in flaxseed and rye bran, e.g. plant oils and fibre, modulated intestinal
adenoma formation in this mouse model. A diet rich in a-linolenic acid may directly
or by changing in the ratio of n-6 to n-3 fatty acids of the intestinal mucosa inhibit
colon tumorigenesis. Fibres may have either some additive chemopreventive or
slightly tumour-growth promotive effects. Fractionation of rye bran did not increase
its anticarcinogenic properties. Subcellular localizations of b-catenin and protein
kinase C-z in the adenoma and mucosa tissue might be pivotal in inhibiting adenoma
formation. A low level of nuclear b-catenin in the adenomas of 7-
hydroxymatairesinol-fed mice and a high level of protein kinase C-z in the mucosal
membranes of flaxseed-fed mice were associated with a low tumour number and size
in  this  animal  model.  The  amount  of  COX-2  was  shown  to  increase  during  tumour
growth, but the experimental diets did not affect the level of this enzyme in the
adenomas. Thus role of COX-2 in tumour progression remained unclear.
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PGE2 prostaglandin E2
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transforming factor b
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91 Introduction
1.1 Lignans
1.1.1 Origin and structure
Plants contain a large group of non-nutrient (poly)phenolic compounds which are
synthesized to protect plants from photosynthetic stress, reactive oxygen radicals,
wounds and attackers such as microbes and herbivores. Plant (poly)phenols are
derived from phenylalanine units, and they have in common at least one aromatic ring
structure with hydroxyl group(s). Lignans are a group of plant (poly)phenols. Lignans
are related to lignin, a structural cell wall component of vascular plants. They are both
derived from monolignols, p-coumaryl, coniferyl and sinapyl alcohols (C6C3) via their
respective pathways (Davin & Lewis 2000). They are characterized by the coupling of
two C6C3 units by a bond between positions C8 and C8’ (Moss 2000). Lignans are
ubiquitous in plant roots, stems, leaves, seeds and fruits, and they have been
suggested to be involved in plant defence. Several hundred different lignan structures
have been identified in various plants (Ayres & Loike 1990). The lignans included
here, i.e. 7-hydroxymatairesinol, matairesinol and secoisolariciresinol, lariciresinol,
pinoresinol and syringaresinol, and two mammalian lignans enterodiol and
enterolactone, which are formed in the mammalian body, are shown in Figure 1.
1.1.2 Food sources and dietary intake
The most commonly analysed lignans in edible plants are secoisolariciresinol and
matairesinol (Mazur et al. 1996, Mazur 1998). The highest amount of lignans, mainly
secoisolariciresinol diglycoside, was found in defatted flaxseed meal, which contains
up to 600-700 mg of secoisolariciresinol per 100 g dry weight (Mazur & Adlercreutz
1998). However, in other foods, e.g. cereals, vegetables and fruits and berries, the
levels of secoisolariciresinol and matairesinol are generally low. These lignans are
also found in such beverages as tea, coffee and wine. Although lignans are ubiquitous
in foods, the intake of secoisolariciresinol and matairesinol has been estimated to be
barely 1 mg/day in Western countries, varying greatly between individuals (Strom et
al. 1999, Horn-Ross et al. 2000a, 2002a, de Kleijn et al. 2001, Keinan-Boker et al.
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Figure 1. Structures of dietary lignans from plants and the mammalian lignans
enterodiol and enterolactone (diagrams kindly provided by Professor K. Wähälä’s
research group, Department of Organic Chemistry, University of Helsinki).
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2002, Valsta et al. 2003, Linseisen et al. 2004) (Table 1a). Milder et al. (2005a) have
recently reported that the intake of four plant lignans secoisolariciresinol,
matairesinol, lariciresinol and pinoresinol was 1.2 mg/day in Dutch adults (Table 1b).
1.1.3 Metabolism in human subjects and animals
In foods, lignans occur as glycosidic conjugates, which are hydrolysed by bacterial b-
glucosidases in the gut and then released as aglycones. Gut microflora can metabolize
plant lignans further into mammalian lignans (Axelson & Setchell 1981, Borriello et
al. 1985). The importance of microflora in the metabolism of lignans has been
demonstrated both in germ-free animals (Axelson & Setchell 1981) and in humans by
the administration of antibiotics, which prevented the production of mammalian
lignans (Setchell et al. 1981). Enterodiol and enterolactone, two mammalian lignans
discovered in human urine already in the 1980s (Setchell et al. 1980, Stitch et
al.1980), are the metabolites of the plant lignans secoisolariciresinol and matairesinol,
respectively (Borriello et al. 1985). Enterodiol can be further oxidized to
enterolactone. Other plant lignans are also precursors of mammalian lignans. In vitro
and in vivo experiments have revealed the plant precursors of the mammalian lignans
enterodiol and enterolactone to be secoisolariciresinol, matairesinol, lariciresinol,
cyclolariciresinol (isolariciresinol), pinoresinol, syringaresinol, 7-
hydroxymatairesinol, arctigenin and its glycoside arctiin (Saarinen et al. 2000, 2002b,
Heinonen et al. 2001, Wang 2002, Xie et al. 2003) (Figure  2).  In  addition,  7-
hydroxyenterolactone and enterofuran have been identified as mammalian lignan
metabolites in human urine (Adlercreutz 1995, Liggins et al. 2000). An in vitro study
showed that 7-hydroxyenterolactone was a metabolite of 7-hydroxymatairesinol, and
enterofuran a metabolite of lariciresinol, pinoresinol and secoisolariciresinol
(Heinonen et al. 2001). Some differences in proportions of different lignan
metabolites emerge when comparing results from in vitro and in vivo experiments.
For example, 7-hydroxymatairesinol was converted to both 7-hydroxyenterolactone
and enterolactone in an in vitro incubation with faecal flora (Heinonen et al. 2001),
whereas orally administered 7-hydroxymatairesinol was mainly metabolized
enterolactone in rats (Saarinen et al. 2000).
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Table 1a. Daily intakes (mg/d) of plant lignans matairesinol and secoisolariciresinol in selected Western Countries.
References Population n Matairesinol Secoisolariciresinol Main lignan sources
Strom et al. 1999 Caucasian men in USA 107 46 (3, 1 082) 483 (9, 139 927)1 Black tea, flaxseed bread,
cranberry products
Horn-Ross et al. 2000a  Elderly African-American, Latina and
Caucasian women in California
447 36 1392 Orange juice, coffee
de Kleijn et al. 2001 Postmenopausal Caucasian women in USA 964 19 (12-28) 560 (399-778)3 Fruits (no citrus), breads, cereals,
rice and grains, berries
Horn-Ross et al. 2002a California Teachers Study cohort 111 526 23 (12-33) 85 (48-121)4 -
Keinan-Boker et al. 2002 Middle-aged and elderly Dutch women 17 140 73 (43-106) 988 (676-1 285)3 Grain products, fruit, red and white
wines
Valsta et al. 2003 Finnish men and women 2 862 38 ± 18 396 ± 15715 Seed, cereals, fruits, berries and
vegetables
Linseisen et al. 2004 Premenopausal German women 666 29 (20-39) 529 (274-1 280)3 Nuts and seeds, coffee, bread,
onion/garlic, wine
1-5 Values are 1 median (minimum, maximum); 2 mean; 3 median (25th-75th) percentiles; 4 mean (20th-80th) percentiles; 5 mean ± SD.
Table 1b. Daily intakes (mg/d) of plant lignans in a Dutch population.
References Population n Matairesinol Secoisolariciresinol Lariciresinol Pinoresinol Main lignan sources
Milder et al. 2005a Dutch men
and women
4660 11 (2, 22) 292 (93, 277) 535 (238, 897) 403 (108, 764)1  Beverages, vegetables, nuts and
seeds, bread and fruits
1 Values are mean (10th-90th) percentiles.
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Absorption of lignans occurs as aglycones. Wood-originated lignans are already in
unconjugated form (aglycones) and thus can be absorbed in the upper parts of the
small intestine. Lignans can be reconjugated in the intestinal epithelium during
absorption or in the liver by UDP-glucuronosyltransferases and sulphotransferases
(Dean et al. 2004, Jansen et al. 2005). Additional metabolism beyond glucuronidation
or  sulphation  may  also  occur  in  the  liver;  enterolactone  and  enterodiol  with  extra
hydroxyl groups have been identified in human urine after flaxseed ingestion (Jacobs
et al. 1999). Oxidative metabolism has been suggested to be a means of disposing of
lignans from the mammalian body (Wang 2002). Plasma lignans circulate either as
glucuronide and sulphate conjugates or as free forms. Lignans are excreted in the
urine and via bile into faeces. Enterolactone and enterodiol are excreted in the urine
mainly as glucuronides, sulphatases, and to a minor extent as free aglycones.
Conjugated lignans, which are excreted through bile, undergo enterohepatic recycling
(i.e. lignans are re-excreted via the bile duct into the intestinal tract, deconjugated by
the bacterial b-glucuronidases and sulphatases, and reabsorbed by the intestinal cells)
or they are flushed away in faeces in free form. Most of the lignans are eventually
excreted via faeces and urine in mammalian organisms. Rickard and Thompson
(1998) reported that after ingestion of 3H-secoisolariciresinol diglycoside, over 50%
of the lignans were excreted in faeces and 30% were present in urine. In tissues, the
Pinoresinol
Figure 2. Proposed metabolic pathways of plant lignans to the mammalian lignans
enterofuran, enterodiol, enterolactone and 7-hydroxyenterolactone (modified from
Heinonen et al. 2001, Saarinen et al. 2000, 2002b, Xie et al. 2003).
Lariciresinol
Secoisolariciresinol Matairesinol
Enterodiol Enterolactone
7-Hydroxymatairesinol
7-Hydroxyenterolactone
Arctigenin
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greatest concentrations were in those tissues involved in lignan metabolism, e.g.
intestinal, hepatic, and renal tissues and in blood. Moreover, some lignans were found
in the uterus. The presence of lignans in human semen, saliva, breast aspirate or cyst
fluid and prostate fluid has also been reported (Adlercreutz 1995).
In humans, average levels of enterolactone in serum/plasma are usually less than 30
nmol/l (Stumpf et al. 2000a, Kilkkinen et al. 2001, 2003a, Pietinen et al. 2001, Stattin
et al. 2002). However, inter-individual variation is large, and in individuals
consuming lignan-containing foods, e.g. whole-grain  products,  fruit,  vegetables  and
berries, serum/plasma enterolactone levels may be considerably over 100 nmol/l
(Adlercreutz et al. 1982, Kilkkinen et al. 2001, Johnsen et al. 2004). Interestingly,
lignan-rich food consumption and health-related variables (e.g. smoking) usually
explain only part of this inter-individual variation. The gut microflora has an
important role in lignan metabolism, and the use of antimicrobials decreases
enterolactone concentrations in urine and serum (Setchell et al. 1981, Kilkkinen et al.
2002). Stumpf & Adlercreutz (2003) and Hausner et al. (2004) reported large intra-
individual within-day and day-to-day variations in serum enterolactone
concentrations, and authors suggested that a single measurement of enterolactone is
insufficient to estimate the basal enterolactone level in human subjects.
1.1.4 Biological activities
Currently of interest to researchers of the nutritional and medical sciences are lignans
and other (poly)phenolic compounds due to their antioxidative, anti-inflammatory and
anticarcinogenic activities and possible effects on human health (Liu 2004, Arts &
Hollman 2005). A large body of in vitro and in vivo data has previously been
reviewed by Adlercreutz (1998), Thompson (1998) and Saarinen (2002). Only the (in
vivo) lignan studies considered most significant with regard to cancer prevention are
referred to here.
Mammalian lignans enterolactone and enterodiol have some structural similarity to
endogenous oestrogens and therefore are included in the family of phytoestrogens (i.e.
oestrogenic compounds of plant origin). Mammalian lignans have been reported to
possess low oestrogenic activity, e.g. they can stimulate proliferation and
DNA/protein synthesis of breast cancer cell lines at 1-10 mM concentrations
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(Welshons et al. 1987, Sathyamoorthy et al. 1994, Wang & Kurzer 1997, 1998,
Mousavi & Adlercreutz 1992). High enterolactone and enterodiol concentrations (IC50
values above 10 mM) can also inhibit the growth of ER-positive and ER-negative
breast cancer cells (Wang & Kurzer 1997, Schulze-Mosgau et al. 1998). Weak
estrogens, such as lignans, have been postulated to have oestrogenic or even
antiestrogenic effects depending on the level of endogenous oestrogens (Mousavi &
Adlercreutz 1992, Adlercreutz 1998). The action of lignans is attributed to their
proposed ability to bind to oestrogen receptors (ER)a and b. Compared with 17b-
estradiol, enterolactone has been shown to bind with a low affinity to human ERa and
b and to act as partial agonist and antagonist (Mueller et al. 2004). The interplay of
lignans and ER a/b might result in competition with endogenous oestrogens, thus
modulating the biological activity of oestrogens in target tissues. Furthermore,
enterolactone has been proposed to affect sex hormone production in vitro by
inhibiting the action of steroid-metabolizing enzymes such as aromatase (Adlercreutz
et al. 1993, Wang et al. 1994), an enzyme converting testosterone and
androstenedione to 17b-oestradiol and oestrone, respectively. Lignans have also been
reported to have the ability to enhance the synthesis of sex hormone binding globulin
(SHBG) in vitro (Adlercreutz et al. 1992), and to possess binding affinities to SHBG,
thus modulating the binding of sex hormones (Schöttner & Spiteller 1998). An ER-
independent pathway may be involved as well. Anticancer effects of
secoisolariciresinol diglycoside, enterolactone, enterodiol and 7-hydroxymatairesinol
may, in part, be associated with their antioxidant capacities, as observed in vitro
assays (Prasad 1997, Kitts et al. 1999, Saarinen et al. 2000). In most studies, plant and
mammalian lignan concentrations were at micromolar levels, which can be over one
hundred/thousand-fold the concentrations generally found in the plasma of human
subjects.
Although the action of lignans action has been postulated to occur via ERs, conclusive
evidence for oestrogen-like activity in vivo has not been found. Early studies with
enterolactone showed no clear oestrogenic effects on uterine weight or uterine RNA
synthesis in female mice and rats (Setchell et al. 1981, Waters & Knowler 1982). In
the latter study, enterolactone inhibited oestrogen-stimulated RNA synthesis in the rat
uterine only when administered 22 hours before oestradiol. Saarinen et al. (2000,
16
2002a, 2005) subsequently reported that enterolactone, 7-hydroxymatairesinol,
matairesinol and secoisolariciresinol (50 mg/kg bw) had no
oestrogenic/antioestrogenic activity or aromatase-inhibiting capacity in immature rats,
as judged by uterine growth. Nor did administration of 7-hydroxymatairesinol (50
mg/kg bw or 0.15% diet) cause oestrogenic or antiandrogenic effects in adult male
rats, as judged by male accessory sex gland and testis weights (Saarinen et al. 2000,
2005). Furthermore, enterodiol and enterolactone at concentrations < 1 mM did not
show any activation of a reporter gene via a- and b- type oestrogen receptors
(Saarinen et al. 2000). In these studies, the mechanism of the action of lignans in
DMBA-induced mammary tumours remained partly unknown. Several studies with
young and adult rats have shown that flaxseed supplementation, pure
secoisolariciresinol diglycoside and nortrachelogenin may cause some oestrogen-like
effects in rats, but the effect is dependent on the life stage (Orcheson et al. 1998, Tou
et al. 1998, 1999, Ward et al. 2000, 2001, Saarinen et al. 2005).
Human studies have demonstrated non-consistent effects of flaxseed on endogenous
sex hormone production and metabolism. Shultz et al. (1993) reported no change in
plasma total or free testosterone levels or SHBG level in men consuming 13.5 grams
of  flaxseed  per  day  for  six  weeks.  No  change  in  the  serum  sex  hormone  or  SHBG
levels, or progesterone/17b-estradiol ratio was found after flaxseed (10 g), wheat bran
(28 g) and flaxseed plus wheat bran (10 g + 28 g) feeding in premenopausal women
(Frische et al. 2003). Three studies with postmenopausal women reported that
consumption of flaxseed changed sex hormone levels in the urine or serum (Haggans
et al. 1999, Hutchins et al. 2001, Brooks et al. 2004). Urinary excretion of oestrogen
metabolites were significantly increased after consumption of ground flaxseed (10-25
g per day) (Haggans et al. 1999, Brooks et al. 2004). Hutchins et al. (2001) reported
reduced serum concentrations of 17b-oestradiol and oestrone sulphate, and an
increased serum concentration of prolactin after flaxseed (5-10 g per day). However,
no change in the serum levels of other sex hormones or SHBG were found in this
study. Thus, short-term experiments with flaxseed have yielded no conclusive
evidence for oestrogenic action of lignans. Similarly, no clear changes in the
metabolism of sex hormones or SHBG, which has suggested to be in part responsible
for lowering the risk of hormone-dependent cancers, were detected.
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1.2 Lignans and cancer
1.2.1 Human studies
During the last two decades, the health effects of lignans in humans have received
much attention. In the early 1980s, results of a descriptive study showed that the
urinary excretion of enterolactone was lower in breast cancer patients than in
omnivorous and vegetarian controls (Adlercreutz et al. 1982). Later, the incidence of
so-called Western diseases, including breast, prostate and even colon cancer, was
proposed to be explained by decreased intake of lignans and isoflavones (Adlercreutz
1990). There are three main ways to study the effect of lignans on the risk of various
cancers in humans. In the first approach, urinary or plasma enterolactone levels have
been used as indicators of lignan consumption and metabolism. The drawback of this
approach is that enterolactone may reflect only short-term intake of plant lignans and
may be influenced by the use of antibiotics (Kilkkinen et al. 2002) or individual
variation in metabolism. In the second approach, an estimated intake of plant lignans
has been used as a marker. This approach may provide a good estimation of long-term
exposure to dietary lignans. So far, only matairesinol and secoisolariciresinol have
been included into food databases (Pillow et al. 1999, Horn-Ross et al. 2000b, Valsta
et al. 2003) which may lead to the underestimation of plant lignan intake (Milder et
al. 2005b). The third approach, an indirect analytical method using an in vitro
fermentation of lignan-containing foods with human faecal microflora (Thompson et
al. 1991), has been used to estimate the intake of mammalian lignans and risk of
breast cancer. Observational studies on the relationship between lignans and the risk
of various cancers in human subjects are summarized in Table 2.
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Table 2. Observational studies on the association between lignans and risk of different cancers in human subjects.
References No. of
cases
No. of
controls
Age (years) Medium Lignan Adjusted OR/RR
(95% CI)1
P for
trend
Association
Breast cancer
Ingram et al. 1997 144 144 30-84 Urine END
ENL
MAT
0.73 (0.33-1.64)
0.36 (0.15-0.86)
2.18 (0.83-5.76)
0.288
0.013
0.308
   None
   Negative
   None
Pietinen et al. 2001 194 208 25-75
Premenopausal
Postmenopausal
Serum ENL
ENL
ENL
0.38 (0.18-0.77)
0.42 (0.10-1.77)
0.50 (0.19-1.28)
0.03
0.18
0.10
   Negative
   None
   None
Dai et al. 2002
Dai et al. 2003
250
117
250
117
25-64
Postmenopausal
Urine
Urine
END
ENL
END + ENL
END + ENL
0.43 (0.26-0.71)
0.42 (0.25-0.69)
0.40 (0.24-0.64)
0.50 (0.23-1.10
<0.01
<0.01
<0.01
0.09
   Negative
   Negative
   Negative
   None
Boccardo et al. 2004 18 383 25-79 Serum ENL 0.36 (0.14-0.93)2 -    Negative
den Torkelaar et al. 2001 88 268 50-64 Urine ENL 1.43 (0.79-2.59) 3 0.25    None
Hultén et al. 2002 248 492 51, 58 (means) Plasma ENL 1.1 (0.7-1.7) -    None
Kilkkinen et al. 2004
Olsen et el. 2004
206
381
215
381
25-75
Postmenopausal
Serum
Plasma
ENL
ENL
1.30 (0.73-2.31)
0.93 (0.86-1.01)
0.48
0.09
   None
   None
Zeleniuch-Jacquotte et al.
2004
189
228
189
228
Premenopausal
Postmenopausal
Serum ENL
ENL
1.6 (0.7-3.4)
1.0 (0.5-2.1)
0.13
0.95
   None
   None
McCann et al. 2002 301
439
316
494
Premenopausal
Postmenopausal
Diet END + ENL
END + ENL
0.49 (0.32-0.73)4
0.72 (0.51-1.02)4
-
-
   Negative
   None
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McCann et al. 2004 315
807
593
1 443
Premenopausal
Postmenopausal
Diet MAT + SECO
MAT + SECO
0.66 (0.44-0.98)
0.93 (0.71-1.22)
-
-
   Negative
   None
Linseisen et al. 2004 278 666 Premenopausal Diet MAT
SECO
MAT + SECO
END
ENL
END + ENL
0.58 (0.37-0.94)
1.12 (0.73-1.73)
1.1 (0.72-1.70)
0.61 (0.39-0.98)4
0.57 (0.35-0.92)4
0.61 (0.39- 0.98)4
0.025
0.648
0.837
0.034
0.008
0.034
   Negative
   None
   None
   Negative
   Negative
   Negative
Horn-Ross et al. 2001 1 272 1 610 35-79 Diet MAT
SECO
MAT  + SECO
1.1 (0.89-1.5)
1.3 (1.0-1.6)
1.3 (1.0-1.6)
-
-
-
   None
   None
   None
Horn-Ross et al. 2002a 568 111 526 21-103 Diet MAT
SECO
1.1 (0.8-1.4)
1.2 (0.9-1.6)
0.2    None
   None
Keinan-Boker et al. 2004 280 15 555 49-70 Diet END + ENL  0.7 (0.5-1.1) 4 0.06    None
Prostate and testicular cancers
Stattin et al. 2002 794 2 550 Middle-aged & old Serum ENL 1.08 (0.83-1.39) -    None
Kilkkinen et al. 2003b 214 214 50-69 Serum ENL 0.71 (0.42-1.21) 0.37    None
Stattin et al. 2004 265 525 60 (median) Plasma ENL 1.22 (0.80, 1.86) 0.21    None
Strom et al. 1999 83 107 61 (mean) Diet MAT
SECO
0.89 (0.47-1.66)
1.20 (0.65-2.21)
-
-
   None
   None
Walcott et al. 2002 159 136 18-55 Diet MAT + SECO
END + ENL
0.96 (0.11-8.09)
0.73 (0.21-2.56)
0.27
0.09
   None
   None
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Table 2. Continues
References No. of
cases
No. of
controls
Age (years) Medium Lignan Adjusted OR/RR
(95% CI)1
P for
trend
Association
Colorectal cancer
Lundin 2001 117 232 ? Plasma ENL 0.99 (0.52-1.88) -    None
Endometrial cancer
Horn-Ross et al. 2003 500 470 35-79 Diet MAT
SECO
MAT +SECO
1.6 (0.99-2.4)
0.63 (0.40-0.98)
0.68 (0.44-1.1)
0.07
0.009
0.03
   None
   Negative
   Negative
Ovarian cancer
McCann et al. 2003 124 696 40-85 Diet MAT + SECO 0.43 (0.21-0.85) -    Negative
Thyroid cancer
Horn-Ross et al. 2002b 817 793 20-74 Diet MAT
SECO
MAT  + SECO
0.72 (0.46-1.1)
0.56 (0.35-0.89)
0.68 (0.43-1.1)
0.49
0.009
0.07
   None
   Negative
   None
Premalignant lesions of the cervix
Hernandez et al. 2004 112 183 >18 Plasma END
ENL
2.7 (1.1-6.3)
2.4 (1.0-5.8)
0.01
0.06
   Positive
   None
1 Adjusted odds ratio/relative risk (95% confidence intervals), highest group compared with lowest group
2 Serum enterolactone ? 8 nmol/l compared with serum enterolactone > 8 nmol/l
3 Crude odds ratio.
4 Lignan intakes expressed as the sum of enterolactone and enterodiol production in vitro from foods.
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Three case-control studies have reported an inverse association between
urinary/serum enterolactone and risk of breast cancer (Ingram et al. 1997, Pietinen et
al. 2001, Dai et al. 2002). A later study by Dai et al. (2003) showed only a tendency
for a reduced risk of breast cancer with increasing urinary excretion of mammalian
lignans. They reported, however, a stronger inverse association between urinary
isoflavonoids/lignans and breast cancer risk among women with a high body mass
index or waist:hip ratio. The authors suggested that these overweight women, who
often have a high level of oestrogens and insulin and a low SHBG level and 2-
hydroxyestrone:16a-hydroxylation ratio, may benefit from high intake of
phytoestrogens such as isoflavonoids and lignans. Recently, a follow-up study has
shown that a high serum enterolactone concentration has a strong protective effect on
breast cancer risk in women with palpable cysts (Boccardo et al. 2004). By contrast,
in one prospective case-control study with postmenopausal Dutch women, higher
urinary enterolactone excretion was associated with a non-significant increase in risk
of breast cancer (den Tonkelaar et al. 2001). Serum/plasma enterolactone level was
not associated with risk of breast cancer in four case-control studies nested within
cohorts in Sweden, Finland, Denmark and USA (Hulten et al. 2002, Kilkkinen et al.
2004, Olsen 2004, Zeleniuch-Jacquotte et al. 2004).  In  one  case-control  and  in  two
cohort studies, no associations between intake of lignans and risk of breast cancer
were found (Horn-Ross et al. 2001, 2002a, Keinan-Boker et al. 2004). In three case-
control studies, the intake of mammalian lignans and matairesinol was, however,
inversely associated with the risk of breast cancer in premenopausal women (McCann
et al. 2002, 2004, Linseisen et al. 2004). McCann et al. (2002) reported also that
premenopausal  women  with  at  least  one  A2  allele  of  the cytochrome P450c17a
(CYP17) gene benefit most from a lignan-rich diet (enterolactone: OR 0.12, 95% CI
0.03-0.50). The authors suggested that lignans might provide the greatest protective
effect among women who have high endogenous hormone levels and perhaps a higher
risk for breast cancer. An intervention study by Thompson et al. (2000) with breast
cancer patients showed that dietary flaxseed (25 g/d) reduced the Ki67 labelling index
(a proliferation marker) in tumours, suggesting an anticancer effect of flaxseed.
Studies examining the association between lignans and prostate cancer risk  are
sparse. Serum enterolactone concentration was not found to be protective against
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prostate cancer in three nested case-control studies (Stattin et al. 2002, 2004,
Kilkkinen et al. 2003b). Similarly, intake of lignans was not associated with risk of
prostate or testicular cancer (Strom et al. 1999, Walcott et al. 2002). An intervention
study with prostate cancer patients showed that the consumption of a low-fat (20% of
energy), flaxseed-supplemented (30 g/d) diet affected several biomarkers associated
with prostatic neoplasia (Demark-Wahnefried et al. 2001). The mean proliferation
index was lower, and the apoptotic index higher in the prostate tumours of diet-treated
patients compared with controls. Significant decreases were also found in the levels of
total serum testosterone, free androgen, and total cholesterol in diet-treated patients
compared with baseline measurements. The authors suggested that the low-fat,
flaxseed-supplemented diet might have an influence via a hormonal mechanism
(lignan production) on prostate cancer biomarkers. However, possible effects of fat
restriction and n-3 fatty acids were not discussed. In an intervention study, Bylund et
al. (2003) reported that when rye-bran or wheat-bran bread was fed to prostate cancer
patients, the apoptotic index was increased in biopsies of prostate tumours in the rye-
bran bread group but not in the wheat-bran bread group. However, plasma
enterolactone levels were not associated with changes in the apoptotic index,
indicating that other components of rye bran were involved.
The relationship between lignans and other types of cancers has also been
investigated. No association was found between plasma enterolactone level and risk
of colorectal cancer or  risk  of  cancers  of  the  colon  and  rectum  separately  in  one
unpublished study (Lundin 2001). Horn-Ross et al. (2002b, 2003), however, reported
reduced risks of thyroid and endometrial cancers with a high dietary intake of
secoisolariciresinol. When the subgroups of women were studied further, the authors
found a significantly reduced risk of endometrial cancer with increasing plant lignan
intake among postmenopausal women (OR = 0.57, 95% CI 0.34-0.97, Ptrend = 0.02).
However, among premenopausal women, no such association was not observed (OR
= 0.77, 95% CI 0.26-2.3, Ptrend = 0.42). In line with these two studies, an inverse
association was detected between the intake of plant lignans and the risk of ovarian
cancer (McCann et al. 2003). In a recent study, Hernandez et al. (2004) reported a
positive association between plasma enterodiol levels and premalignant lesions of
the cervix.
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In summary, observational studies have yielded contradictory results on the
relationship between lignans and risk of different cancers. Out of 16 case-control and
cohort studies, eight showed an inverse association between lignans and breast cancer
risk, and eight found no clear evidence of such an association. All five studies of
lignans and risk of prostate/testicular cancers showed null results. Among five studies
of lignans and risks of colorectal, endometrial, ovarian and thyroid cancers, or risk of
premalignant lesions of the cervix, one study was null, three studies showed low risks
and one study showed an elevated risk. The results of these studies are, however, only
preliminary, and requiring confirmation by future research. It is also noteworthy that
in some studies the association between lignans and risks of cancers was dependent
on menopausal status or cytochrome P450c17a (CYP17) allele status. This may
indicate that certain subgroups of women benefit more by increasing lignan intake.
This suggestion requires verification in future studies.
1.2.2 Animal studies
The effects of lignan-rich foods or pure lignan isolates on breast, prostate and colon
cancers in experimental animals are summarized in Table 3. In most studies, flaxseed
has been used as a model substance to test the effect on lignans in carcinogenesis.
Flaxseed  and  defatted  flaxseed  at  a  level  of  2.5  -  10%  level  have  been  shown  to
reduce risks for mammary cancer in dimethylbenz(a)anthracene (DMBA)-treated
rats during initiation and the early and late promotion stages of the cancer process
(Thompson et al. 1996a, b, Thompson 1998). Similarly, purified lignan
secoisolaricaresinol diglycoside at 1.5 mg/d inhibited the development of new
tumours in this rat model (Thompson et al. 1996a, b). Ground flaxseed, rich in lignans
and n-3 fatty acids, has been shown to decrease the growth rate and metastasis of
oestrogen receptor (ER)-negative human breast cancer cells in nude mice (Chen et al.
2002, Dabrosin et al. 2002). In contrast to these studies, 2.5-5% ground flaxseed or
secoisolaricaresinol diglycoside at 0.7-1.4 mg/d gave inconsistent results in N-methyl-
N-nitrosourea-treated rats: low secoisolaricaresinol diglycoside level promoted, high
secoisolaricaresinol diglycoside level inhibited and flaxseed feeding had no effect on
tumour multiplicity (Rickard et al. 1999). Authors concluded that discrepancies
between this and previous studies on flaxseed might be related to differences in
experimental design, e.g. the use and dose of a different carcinogen and a basal diet.
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Table 3. Effects of lignans or lignan-rich diets on breast, prostate and colon cancers in experimental animals.
References Model Lignan intake or experimental diet Effect ( compared with controls)
Breast cancer
Thompson et al. 1996a DMBA-treated rats
(late promotion stage) 1
SDG 2 200 nmol per day 2, 1.82%
flaxseed oil 3, flaxseed 2.5% and 5%
All experimental diets reduced the volume of established
tumours by at least 50%. SDG intake reduced the volume of
new tumours.
Thompson et al. 1996b DMBA-treated rats
(early promotion stage) 1
SDG 1.5 mg per day 2 SDG intake reduced the number of tumours per tumour-
bearing rat by 37%, and the number of tumours per total
number of rats by 46%.
Rickard et al. 1999 MNU-treated rats
(early promotion stage) 1
SDG 0.7 and 1.4 mg per day, 2.5% and
5% ground flaxseed
No effect of flaxseed diets on tumour size, multiplicity or
incidence was observed. Low SDG level promoted and high
SDG level inhibited tumour multiplicity. All treatment groups
showed decreased tumour invasiveness and grade.
Chen et al. 2002 ER-negative human breast
cancer cells in nude mice
(late promotion stage) 1
Ground flaxseed 10% Flaxseed diet decreased tumour growth rate, total incidence of
metastasis (by 45%), proliferation and expression of insulin-
like growth factor 1 and epidermal growth factor receptor in
tumours.
Dabrosin et al.2002 ER-negative human breast
cancer cells in nude mice
(late promotion stage) 1
Ground flaxseed 10% Flaxseed diet decreased tumour growth rate, incidence of
metastasis in other organs and extracellular levels of vascular
endothelial growth factor.
Hirose et al. 2000 PhIP-treated rats (initiation and
promotion stages) 1
Arctiin 0.2% and 0.02% Arctiin given in post-initiation period decreased the
multiplicity (but not the incidence) of tumours.
Kitamura et al. 2003 PhIP-treated rats (initiation and Trachelogenin 0.2% and 0.02% Trachelogenin did not decrease tumour incidence or inhibit
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promotion stages) 1 the growth of mammary tumours.
Saarinen et al. 2000 DMBA-treated rats
(late promotion stage) 1
HMR extract 15 mg per kg bw per day HMR extract reduced the total tumour volume and increased
the proportion of regressing and non-growing tumours.
Saarinen et al. 2001 DMBA-treated rats (initiation
and late promotion stage) 1
HMR extract 4.7 mg per kg bw
(pure HMR 87.6 mg per kg diet)
HMR intake when started one week before the DMBA
treatment decreased tumour growth rate and total tumour
volume at the end of the feeding period by 22%.
Saarinen et al. 2002a DMBA-treated rats
(late promotion stage) 1
ENL 1 and 10 mg per kg bw ENL at 10 mg per kg reduced the total tumour volume, and
the total volume of new tumours established during the
experiment.
Saarinen et al. 2005 DMBA-treated rats
(late promotion stage) 1
Nortrachelogenin 15 mg per kg bw Nortrachelogenin did not inhibit the growth of mammary
tumours.
Prostate cancer
Landström et al. 1998 Antrogen-sensitive prostate
tumour implants in rats
Defatted soy flour 33%, rye bran 33%,
rye- endosperm 33%, heat-treated rye
bran 33%
Soy flour and rye-bran intake delayed tumour growth at early
stages.
Bylund et al. 2000 Antrogen sensitive human
tumour cells in nude mice
Rye-bran 30% Rye-bran intake inhibited tumour growth and lowered
prostate-specific antigen secretion.
Zeng et al. 2004 SV40T antigen transgenic rats Arctiin 0.004%, 0.02% and 0.1% No significant effect of arctiin on neoplastic lesions of the
prostate was observed
Bylund et al. 2005 LNCaP human prostate cancer
xenografts in athymic mice
(early promotion stage) 1
HMR 0.15% and 0.30% HMR intake mice decreased tumour growth and tumour cell
proliferation index (0.30% HMR), and increased apoptotic
index.
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Table 3. Continues
References Model Lignan intake or experimental diet Effect ( compared with controls)
Colon cancer
Serraino & Thompson
1992
AOM-treated rats
(early promotion stage) 1
Flaxseed flour (ground flaxseed) 5%
and 10%, defatted flaxseed meal 5%
and 10%
All experimental diets reduced the number of ACs by 41-53%
and ACF by 48-57% in the descending (distal) colon.
Jenab & Thompson
1996
AOM-treated rats
(early promotion stage) 1
SDG 1.5 mg per day 3, flaxseed 2.5%
and  5%, defatted flaxseed 2.5% and
5%
SDG intake reduced the total number of ACs by 29% in the
distal colon. All experimental diets reduced the number of AC
per focus (AC multiplicity) in the distal colon.
Davies et al. 1999 AOM-treated rats
(initiation stage) 1
Rye bran 30% Rye-bran diet decreased the number of tumours in the colon.
Mutanen et al. 2000 Min mice Rye bran 10% Rye-bran group had a tendency to gain lower amounts of
adenomas in the small intestine than the non-fibre group.
van Kranen et al. 2003 Min mice Rye bran 30%, flaxseed 5% No protective effect of rye bran or flaxseed on intestinal
adenoma formation was observed.
Hirose et al. 2000 PhIP-treated rats (initiation and
promotion stages) 1
Arctiin 0.2% and 0.02% Arctiin given during the post-initiation period decreased the
total number of ACF
Abbreviation are explained on page 8.
1 Animals put on experimental diets before the carcinogen treatment/cancer cell injection (initiation stage), shortly after the carcinogen treatment/cancer cell injection (early
promotion stage) or several weeks after the carcinogen treatment (late promotion stage).
2 Lignan dose is equivalent to that present in 15 g of 5% flaxseed diet.
3 Fatty acid dose is equivalent to that present in 15 g of 5% flaxseed diet.
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The antitumour effect of various flaxseed-containing diets appeared not to be dose-
dependent, and a higher level of flaxseed did not provide extra protection against
tumorigenesis. The exact mechanism of lignan action during different stages of
mammary tumorigenesis was not elucidated, although the possible mechanism of
lignan protection was supposed to be associated to the factors reviewed in the section
entitled “Biological activities” (page 14). In addition, antitumour effects of flaxseed
were linked with reduced expressions of insulin-like growth factor-1, epidermal
growth factor receptor and vascular endothelial growth factor in ER-negative tumours
(Chen et al. 2002, Dabrosin et al. 2002). Flaxseed also contains high quantities of a-
linolenic acid (18:3n-3), which may inhibit the cancer process. Thompson et al.
(1996a) reported that flaxseed oil-supplemented diet (equal to a level of 5% flaxseed)
inhibited tumour growth when mammary tumours were already established but had no
effect on new tumour development. With regard to pure lignan isolates, arctiin, 7-
hydroxymatairesinol and enterolactone have been shown to inhibit mammary
carcinogenesis in carcinogen-treated rats (Hirose et al. 2000, Saarinen et al. 2000,
2001, 2002a) but tracheloside or nortrachelogenin administrations had not such
effects in carcinogen-treated rats (Kitamura et al. 2003, Saarinen et al. 2005).
The effect of lignans on prostate cancer is unclear. Landström et al. (1998)
suggested that phytoestrogens (isoflavonoids of soy and lignans of rye bran) might be
responsible for delayed prostate tumour growth in rats. In a subsequent study,
consumption of a rye-bran diet (30%) delayed prostate cancer growth in nude mice,
but the effect was not related to enterolactone production (Bylund et al. 2000). Two
studies with pure lignans showed conflicting results. Arctiin from Arctium lappa
(burdock) seeds failed to prevent prostate cancer in SV40T antigen transgenic rats
(Zeng et al. 2004) whereas 7-hydroxymatairesinol inhibited tumour growth of the
LNCaP human prostate cancer xenografts in athymic mice (Bylund et al. 2005).
The impact of lignans on colon carcinogenesis has  been  studied  mainly  with
carcinogen-treated rats, with formation of early precancerous lesion (aberrant crypt
foci, ACF) or tumour in the colon being used as an end-point (Serrano & Thompson
1992, Jenab & Thompson 1996, Davies et al. 1999, Hirose et al. 2000). Flaxseed and
defatted  flaxseed  meal  (at  a  level  of  5% or  10%) decreased  the  number  of  aberrant
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crypts  (AC)  and  ACF  in  the  descending  (distal)  colon  of  carcinogen-treated  rats  by
41-53% and 48-57%, respectively (Serraino & Thompson 1992). However, the effect
of  flaxseed  was  not  dose-dependent.  Nor  was  it  related  to  the  urinary  excretion  of
mammalian lignans or the presence of a-linolenic acid in the diets. In a subsequent
study, where carcinogen-treated rats were fed either a control diet or a diet
supplemented with flaxseed and defatted flaxseed meal (at level of 2.5% or 5%) or
pure secoisolariciresinol diglycoside, the number of AC per focus (AC multiplicity)
was significantly reduced in the distal colon of flaxseed and secoisolaricaresinol
diglycoside groups (Jenab & Thompson 1996). The protective effect was partly due to
secoisolaricaresinol diglycoside, and there was a negative association between total
urinary lignan excretion and AC multiplicity. The oil component of flaxseed was not
considered  an  effective  agent  in  this  study.  In  other  study,  a  30%  rye-bran  diet
decreased the number of colon tumours in carcinogen-treated rats, and the authors
suggested that the rye-bran lignans were responsible for this effect (Davies et al.
1999). Similarly, Mutanen et al. (2000) reported that multiple intestinal neoplasia
(Min) mice fed rye bran had the lowest adenoma number (26.4 ± 12.1, mean ± SD)
and incidence of colon adenomas (33%) of all experimental groups, although these
values were not significant when compared with the non-fibre group (34.6 ± 7 and
71%). However, lignans were not measured in this study, and their role in tumour
prevention remained unclear. Later, van Kranen et al. (2003) reported that flaxseed or
rye-bran consumption did not explain adenoma formation in Min mice. Only one
study has evaluated the role of pure lignan isolate in colon carcinogenesis (Hirose et
al. 2000). When pure lignan arctiin from Arctium lappa (burdock) seeds were fed to
carcinogen-treated rats, the number of ACF per colon was significantly decreased in
the group fed 0.02% arctiin during the initiation period, and in groups fed either
0.02% or 0.2% arctiin during the post-initiation period.
Yan et al. (1998) and Li et al. (1999) have reported on the effects of flaxseed and pure
secoisolaricaresinol diglycoside on experimental metastasis of melanoma cells in
mice. In both studies, B16BL6 murine melanoma cells were injected into C57BL/6
mice, which resulted in the formation of metastatic lung tumours. Flaxseed at levels
of 5% and 10% reduced tumour area, tumour volume and the median number of
tumours by 54% and 63%, respectively (Yan et al. 1998). In the second study,
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secoisolaricaresinol diglycoside at 147 and 293 mmol/kg reduced tumour area and
tumour volume. However, only the highest secoisolaricaresinol diglycoside level
(equivalent to a 10% flaxseed diet) reduced the median number of tumours by 53%
(Li et al. 1999). This indicates that flaxseed per se is more potent in preventing
metastasis than an equivalent amount of pure secoisolaricaresinol diglycoside.
In summary, experimental studies of lignans or lignan sources and mammary and
colon carcinogenesis showed both protective and neutral effects. Secoisolaricaresinol
diglycoside from flaxseed, arctiin, 7-hydroxymatairesinol and enterolactone have
been the most potent anticarcinogenic compounds in animal studies. However, the
role of the oil component of flaxseed in tumour prevention remains obscure, and may
be underestimated. The effect of lignans or sources of lignans on prostate
carcinogenesis in animals and humans seem not to be convincing. Only one study
showed that 7-hydroxymatairesinol had anticancer properties on a prostate cancer
model. The potential antitumourigenic effects of lignans or lignan-rich foods may
involve both ER-mediated and ER-independent mechanisms.
1.3 Colon carcinogenesis
1.3.1 Colorectal cancer
Colorectal cancer is the third most common cancer (9.4%) worldwide after lung and
breast cancers. It ranks fourth in mortality (7.9%), after lung, stomach and liver
cancers (Stewart & Kleihues 2003). Nearly 950 000 new colorectal cancer cases are
diagnosed yearly, with over 490 000 deaths. It affects men and women almost
equally, with about 498 000 new cases in men and 446 000 in women per year.
Incidence rates of this cancer are highest in North America, Europe, Australia and
Japan, and lowest in Africa and Asia. In Finland, three leading cancers in 2003 were
lung, prostate and colorectal cancer in men with incidence rates of 95, 34 and 26 per
100 000, respectively. Women’s leading cancers in 2003 were breast, colorectal and
corpus uteri cancers with incidence rates of 84, 19 and 14 per 100 000, respectively
(Finnish Cancer Registry, http:// www.cancerregistry.fi/eng/statistics/ updated
11.7.2005).
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Colorectal cancer mainly occurs sporadically and is affected by both genetic and
environmental factors (Weitz et al. 2005). Ethnic, migrant and twin studies show that
environmental factors, including diet, are the strongest contributors to cancer risk,
accounting for over 70% of colorectal cancers (Willet 2002, Stewart & Kleihues
2003). Diets high in vegetables and fruits, and perhaps fibre, and low in fat and red
meat have been suggested to be associated with a decreased risk of colorectal cancer
(Potter 1999). In addition, the use of nonsteroidal anti-inflammatory drugs or
hormone replacement therapy has consistently been associated with a reduced risk of
colorectal cancer (Grodstein et al. 1999, Writing Group for the Women’s Health
Initiative Investigators 2002, Hawk et al. 2004). Physical activity also appears to
confer some protection (Potter 1999).
Colorectal cancer is inherited in approximately 5-10% of cases. The two most
common inherited forms are familial adenomatous polyposis (FAP) and Lynch
syndrome, also known as hereditary non-polyposis colorectal cancer (de la Chapelle
2004). FAP patients have hundreds to thousands of adenomas throughout the colon
and rectum. Germline mutations in the adenomatous polyposis coli (APC) gene
underlie FAP (Nishisho et al. 1991), and the penetrance of this syndrome is nearly
100%.  Lynch  patients  are  prone  not  only  to  colorectal  cancer  but  also  to  cancer  of
other organs, such as the endometrium, ovaries, stomach and small intestine, which
hinders diagnosis of the syndrome (Lynch & de la Chapelle 2003, Lynch et al. 2004).
Germline mutations in the mismatch repair genes, including MLH1, MSH2 and
MSH6, cause Lynch syndrome, and the syndromes’ penetrance is approximately 80%
for colorectal cancer. Microsatellite instability was described as a hallmark of Lynch
syndrome (Aaltonen et al. 1993).
Most cancer-causing mutations occur in somatic cells, and sporadic colorectal
carcinomas arise from a multistage process in which epithelial cells harbour multiple
genetic changes in tumour-suppressor genes and proto-oncogenes (Fearon &
Vogelstein 1990, Kinzler & Vogelstein 1996). Some of the genetic changes
underlying intestinal tumour progression are summarized in Figure 3. The adenoma-
carcinoma sequence is widely accepted to be one of the main pathways, and the APC
tumour-suppressor gene to be one of the first genes mutated during intestinal
neoplasia (Powell et al. 1992). The APC gene is mutated in 80% of sporadic colon
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Figure 3. Colorectal carcinomas arise from a multistage process (black arrows) in which
epithelial cells harbour multiple genetic changes in tumour-suppressor genes and proto-
oncogenes (dashed arrows) (modified from Fearon & Vogelstein 1990, Potter 1999 and Fodde
et al. 2001). The majority of sporadic tumours are suggested to develop via an APC-
dependent pathway. APC, adenomatous polyposis coli; KRAS, a proto-oncogene coding a
signalling protein; LKB1, a serine/threonine kinase gene; LOH, loss of heterozygosity (in cells
that carry a mutated allele of a tumour-suppressor gene, the gene becomes fully inactivated
when the cell loses a large part of the chromosome carrying the wild-type allele); MMR genes,
mismatch repair genes; p53, a gene coding a multifunction tumour-suppressor protein; PTEN,
a tumour-suppressor gene coding a protein that attenuates signals originating at tyrosine
kinase receptors, e.g. insulin-like growth factor 1 receptor; SMAD3/4, genes coding signaling
proteins downstream of  transforming factor b.
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cancers and in all patients with FAP, and is followed by mutation or loss of other
tumour-suppressor genes (p53 and SMAD2/4) and mutation of the KRAS proto-
oncogene. In addition to a mutation in one allele, inactivation of tumour-suppressor
genes requires losses of a part of the chromosome carrying the wild-type allele (loss
of heterozygosity, LOH). The APC-related  pathway  of  transformation  is  typical  of
distal (left) colorectal cancers, whereas proximal (right) colorectal cancers more often
possess microsatellite instability and defects in mismatch repair genes. A differential
pattern of gene expression between the proximal and distal colon may, in part, cause
the tissues’ susceptibilities to certain pathways of tumorigenesis (Glebov et al. 2003).
The APC protein is a huge multifunction protein which contains 2 843 amino acids
and regions that interact with several proteins, including axin/conductin, b-catenin,
tubulin and microtubule-associated protein EB1 (Fodde et al. 2001). Thus, APC is
involved in cellular adhesion, migration, signalling and proliferation. Interested
readers are referred to an extensive review of the various functions of APC and their
roles in colon cancer (Näthke 2004). One well-studied role of APC is in a Wnt
signalling. In the cytosol, the APC protein together with glycogen synthesis kinase 3
beta (GSK3b) and axin/conductin post-transcriptionally regulate the level of b-catenin
protein (Behrens et al. 1998, Hart et al. 1998). This complex phosphorylates b-
catenin, thus targeting it for ubiquitination and destruction by proteasomes. In the
presence of Wnt signalling, a dishevelled (Dsh) protein inhibits APC/GSK3b/axin
activity so that more b-catenin is present in cells. In cancer, a dysfunction in the APC
protein causes, among other things chromosomal instability in epithelial cells and
improper regulation of cellular b-catenin pools (Henderson 2000, Fodde et al. 2001).
Mutations in the APC gene lead to the accumulation of hypophosphorylated b-catenin
protein in the cytosol and later in the nucleus, where b-catenin together with
transcription factors (T cell factor/lymphoid enhancer-binding factor) (Behrens et al.
1996, Korinek et al. 1997) constitutively activate the expression of target genes such
as C-myc and cyclin-D1 (He et al. 1998, Tetsu & McCormick 1999). In addition,
genes coding for matrix metalloproteinase matrilysin, peroxisome proliferator-
activated receptor d (PPARd), components of the AP-1 transcription complex (c-jun
and fra-1), urokinase-type plasminogen activator receptor (uPAR), zonula occludens-
(ZO-1) and vascular endothelial growth factor (VEGF) have been identified as target
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genes for the b-catenin/Tcf complex (Crawford et al. 1999, He et al. 1999, Mann et
al. 1999, Easwaran et al. 2003).  The  role  of b-catenin in intestinal tumorigenesis is
further supported by b-catenin mutations with a stable phenotype being found in
colorectal tumours lacking APC mutations (Morin et al. 1997, Sparks et al. 1998). b-
Catenin binds also to E-cadherin and a-catenin in the adherent junction complexes,
which form homophilic interactions between neighbouring cells and anchor to actin
filaments (Cowin 1994). Thus, b-catenin has an important role in maintaining cell-cell
contacts.
1.3.2 ApcMin/+ (Min) mice as a model of colon carcinogenesis
Colon carcinogenesis can be studied either by inducing ACF or tumour formation
with chemical carcinogens or by using mouse models with defects in the Apc gene
(Green & Hudson 2005). One such mouse model for human FAP is multiple intestinal
neoplasia (Min) or ApcMin/+ mice, which was generated by random chemical
carcinogenesis of C57BL/6J mice (Moser et al. 1990). Some of the progeny had a
phenotype characterized by multiple adenoma formation in the small intestine and
colon, and therefore, the gene defect was named multiple intestinal neoplasia. Most of
the intestinal adenomas (range 30-100) were in the small intestine, especially in the
distal  part,  and  only  a  few adenomas  were  found in  the  colon.  The  lifespan  of  Min
mice was around 120 days, and the cause of death was severe chronic anaemia and/or
intestinal obstruction. Breeding studies showed that tumour development was
dependent on a single dominant mutant allele, and the Min character was transmitted
to 50% of progeny. The germline mutation was later mapped to mouse chromosome
18, and it appeared to be a transversion point mutation that alters nucleotide 2549
from a T to an A in the Apc allele (Su et al. 1992). This converts codon 850 from one
encoding a leucine to a stop codon, which in turn causes truncated Apc protein
formation. Heterozygous Min mice had one wild-type and one mutated Apc allele in
all somatic and gemline cells. Mice homozygous for the Min mutation died at the
latest on day seven of gestation (Moser et al. 1995). Intestinal adenomas in Min and
in other Apc-deficient mice were homozygous for the Apc defect,  and  loss  of  the
chromosome carrying the wild-type Apc allele preceded intestinal tumour
development (Oshima et al. 1995). Inactivation of the normal APC allele has also
been shown in tumours of FAP patients (Levy et al. 1994, Lamlum et al. 1999).
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Mutations in the APC gene predispose people to colorectal cancer, whereas in Min
mice, due to their short life span, most of the tumours are benign adenomas, or
sometimes adenocarcinomas, but never metastatic tumours. Mutations in KRAS and
p53 genes have not been found in Min mice.
Other genes can modify tumour multiplicity in Min mice. Dietrich et al. (1993)
reported that tumour number in Min mice was strongly affected by genetic
background. A modifier  of  Min1 (Mom1) locus accounts for about 50% of genetic
variation in tumour number in two mouse strain backcrosses. A candidate for Mom1 is
the gene for a secretory phospholipase A2 (sPLA2). PLA2s  represent  a  family  of
proteins which cleave membrane phospholipids at the sn-2 position, releasing free
fatty acids, including arachidonic acid (Bilger et al. 1996). Cyclooxygenase-2 (COX-
2) enzyme converts arachidonic acid to prostaglandins such as PGE2. A large body of
data supports the important role of COX-2 in colonic neoplasia (Gupta & Dubois
2001). COX-2 expression is elevated in human adenomas and adenocarcinomas and
in adenomas of Min mice (Ebenhard et al. 1994, Williams et al. 1996). Moreover, in
an Apc mutated background, mice null for COX-2 had suppressed polyp formation
(Oshima et al. 1996). The risk of colorectal adenoma in human subjects has recently
been reported to be modified by single nucleotide polymorphisms in genes related to
the arachidonic acid pathway such as secretory and cytosolic PLA2 and COX-2
(Siezen et al. 2005). Taken together, these studies have shown the relevance of
cellular fatty acid metabolism in colonic neoplasia.
Hormonal factors also seem to play a role in the progression of colorectal cancer in
humans since hormone-replacement therapy in postmenopausal women decreases the
risk of colorectal cancer (Grodstein et al. 1999, Writing Group for the Women’s
Health Initiative Investigators 2002, Hawk et al. 2004). The protective mechanism is
unclear, but a decrease in secondary bile acid concentration by oestrogen or a direct
effect of oestrogen on epithelial cells has been suggested (McMichael & Potter 1980).
A more recent hypothesis involves ERb, which was cloned in 1996 (Kuiper et al.
1996) and found also to be present in the intestinal mucosa of the colon (Foley et al.
2000). Endogenous oestrogen was also demonstrated to protect against Apc-induced
tumour formation, and this protection was associated with a relative increase in ERb
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and a decrease in ERa in intestinal tissues (Weyant et al. 2001). Later the same study
group showed that treatment of ovaryectomized Min mice with 17b-estradiol and the
phytooestrogen coumestrol, but not the soy isoflavone genistein, resulted in a
significant reduction in tumour number (Javid et al. 2005). The data reported thus far
suggest that both endogenous oestrogen and functional ERb may protect against colon
cancer. The proposed actions of lignans in colon tumorigenesis might be direct (inside
the intestinal lumen) or indirect (systemic via blood), possibly being mediated though
the ER. However, ER-independent mechanisms may also be involved.
In summary, the genetic background (defect in Apc gene) and phenotype (formation
of multiple intestinal adenomas) are similar to Min mice and human FAP patients,
with  the  exception  that  in  Min  mice  most  of  the  adenomas  are  found  in  the  small
intestine. Despite this, Min mice are considered a suitable model for studying
development of intestinal neoplasia. Precancerous lesions (adenomatous polyps and
ACF)  are  also  considered  one  of  the  strongest  end-point  markers  for  dietary
chemoprevention studies in animals and in human subjects (Rafter et al. 2004).
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2 Aims of the study
Based on epidemiological findings and experimental studies, lignans or sources of
lignans, such as flaxseed and rye bran, might have a role in colon cancer prevention.
The objective of this study was to investigate the effects of plant and mammalian
lignans on adenoma formation in Min mice, which serve a model for colon
carcinogenesis. Mice were fed diets supplemented with lignan-containing foods, e.g.
flaxseed (I, II), rye-bran and its extracts (III), and pure wood-originated lignans 7-
hydroxymatairesinol (IV), matairesinol and secoisolariciresinol (V). The formation of
the mammalian lignans enterolactone and enterodiol was analysed from intestinal
contents and plasma (I-III, V) to determine whether the effect of lignans on adenoma
formation in Min mice is direct or systemic. These studies were designed to answer
the following questions:
1. Do lignan-rich diets have an effect on intestinal adenoma formation in Min mice?
2. Is there an association between plasma enterolactone level or intestinal lignans and
adenoma formation?
3. Are there gender or genotypebased differences in lignan metabolism and adenoma
formation?
4. Are there some dietary components in flaxseed and rye bran besides lignans which
might be related to adenoma formation?
5.  Does  a  lignan-rich  diet  affect  cell-signalling  parameters,  such  as b-catenin,
cyclooxygenase-2 and protein kinase C, in the intestinal tissues of Min mice?
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3 Study designs and methods
This section gives a brief overview of study designs and methods. Detailed
descriptions of materials and methods can be found in the original publications (I-V).
3.1 Diets and study designs
All diets were semi-synthetic AIN-93G-based (Reeves et al. 1993) high-fat diets. The
fat concentration (20 g/100 g) and fat composition of the experimental diets were
designed to approximate those in a typical Western-type diet; the diet provided
intakes of saturated, monosaturated and polysaturated fatty acids in an approximate
ratio of 3:2:1. The bran/fibre- supplemented diets were prepared by diluting non-fibre
with the addition of a bran/fibre source, and take into account the protein,
carbohydrates and fat provided by brans. All diets were similar with respect to protein
(20%), carbohydrates (40%) and fat (40%) on an energy basis (kJ), excluding the
energy values contained in dietary fibre and derived from fermentation. Lignan levels
of the experimental diets and estimated lignan intakes in Studies I-V are summarized
in Table 4.
Flaxseed is the richest source of lignans in food, and it has been used as a model
substance in experimental studies of the relationship between lignans and cancer.
Studies I and II were designed to test the effect of flaxseed lignans, mainly
secoisolariciresinol diglycoside, on adenoma formation in Min mice. Both intestinal
lignan levels and plasma enterolactone levels were analysed. Male and female Min
mice and wild-type mice were used in Study I to determine whether conversion plant
lignans differ between the sexes, and whether a genotype-based difference exists in
lignan metabolism between Min and wild-type mice. In Study II, the flaxseed mixture
diet was composed such that the level of defatted flaxseed was five times higher than
in Study I. Furthermore, to elucidate the role of the oil component of the flaxseed
mixture  in  adenoma formation,  a  lignan-free  diet  with  an  oil  composition  similar  to
the flaxseed-supplemented diet was made. In Study II, the intestinal lignan level, the
plasma enterolactone level, the fatty acid composition of the colon mucosa and cell
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Table 4. Lignan levels of experimental diets, and estimated lignan intakes in Studies I-V.
Study Diets Lignan level/kg diet  Estimated lignan intake/day
bw kg in aglycone form3
mmol mg mmol mg
I Non-fibre (control) <0.23 <0.1  - -
Defatted flaxseed 0.5% 73 26  7 2.5
II Non-fibre (control) nd1 nd1  - -
Flaxseed mixture 15% 3802 1402  38 13
Oil mixture 9% nd1 nd1  - -
III Non-fibre (control) 0.4 0.1  - -
Rye bran 10% 15.4 5.5  1.4 0.5
Soluble extract 7.9% 20.5 7.3  2 0.7
Insoluble extract 7.9% 7.5 2.7  <1 <0.26
IV Inulin 2.5% (control) nd1 nd1  - -
Inulin 2.5%  + Rye bran 10% nd1 nd1  - -
Inulin 2.5%  + 7-hydroxy-
matairesinol extract 0.02%4
260 94  25 9
V Non-fibre (control) nd nd  - -
Matairesinol 0.02% 560 200  50 20
Secoisolaricirecinol 0.02% 560 200  50 20
1 nd, not determined.
2 Calculations were based on the lignan level of defatted flaxseed (5 mg/g) in Study I.
3 Food consumption per mouse was estimated to be 2.4 g per day.
4 Extract contained 47% 7-hydroxymatairesinol.
signalling parameters, such as b-catenin, cyclooxygenase-2 and protein kinase C-z,
were analysed.
Study III evaluated whether two rye-bran fractions, i.e. the soluble extract and the
insoluble fraction, result in distinct bifidogenic effects or enterolactone production in
Min mice, and whether these parameters are associated with intestinal tumorigenesis
in this animal model. The fractions of rye bran were prepared on the basis of water
solubility, which resulted in different fibre compositions and in vitro fermentation
properties of the two rye fractions. The spectrum of rye-bran lignans differs from that
of flaxseed, with the main lignan in rye bran being syringaresinol, although
pinoresinol, lariciresinol, secoisolarisiresinol and matairesinol are also found.
Processing of rye bran did not affect relative proportions of various lignans, but total
lignan  concentrations  of  rye  fractions  were  changed.  The  soluble  extract  had  the
highest and the insoluble fraction the lowest lignan concentration. In Study III, the
mice were fed the experimental diets twice, and the two experiments were referred to
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as Experiments 1 and 2. The adenoma and Bifidobacterium results were presented as
pooled from Experiments 1 and 2, and lignan results from Experiment 2 alone.
Methods for isolating wood-originated lignans in large quantities from branch knots
of  Norway  spruce  (Picea abies) are available (Ekman 1976). The major lignan
isolated from branch knots is 7-hydroxymatairesinol, which represents up to 60% of
all isolated lignans. 7-Hydroxymatairesinol can be used as a starting material for
chemical synthesis to produce other pure lignans, e.g. matairesinol and
secoisolariciresinol. Studies IV and V were  carried  out  to  test  the  effects  of  pure
lignans 7-hydroxymatairesinol (IV), matairesinol and secoisolariciresinol (V) on
adenoma formation in Min mice. Subcellular expression of b-catenin was analysed in
the adenoma and mucosa tissues in Study IV.
3.2 Sources of lignans
Defatted flaxseed came from Elixi Oil Oy (Somero, Finland), and flaxseed
(Linobene®) and oil mixtures from HK-Ruokatalo (Vantaa, Finland). Dr. Sirpa
Karppinen (VTT, Espoo, Finland) prepared and analysed the insoluble fraction and
the soluble extract of rye bran as described in Study III. Rye bran was purchased from
Melia (Raisio, Finland).
The isolation and composition of the (–)-7-hydroxymatairesinol extract from Norway
spruce (Picea abies) was similar to that described by Saarinen et al. 2000. The isolate
was a gift from Hormos Medical Ltd. (Turku, Finland), and it contained 47% 7-
hydroxymatairesinol, 17% other lignans (liovil, secoisolariciresinol, conidendric acid,
matairesinol, lignan A, conidendrin and lariciresinol) and 36% polar, non-volatile,
high molecular weight organic components. 7-Hydroxymatairesinol was a mixture of
two diastereomers, (–)-7-hydroxymatairesinol (major isomer) and (–)-7-allo-
hydroxymatairesinol (minor isomer) (Mattinen et al. 1998).
(–)-Matairesinol was synthesized from 7-hydroxymatairesinol isolated from Norway
spruce according to Eklund et al. (2003). (–)-Secoisolariciresinol was synthesized
from matairesinol by reduction with LiAlH4 essentially as described by Eklund et al.
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(2002). Purities of the synthesized compounds were over 95%. Associate Professor
Rainer Sjöholm’s research group (Åbo University, Finland) provided both
matairesinol and secoisolariciresinol for diet experiments.
3.3 Experimental animals
The Laboratory Animal Ethics Committee of the University of Helsinki approved the
study protocols of all experiments (I-V). Male C57BL/6J- ApcMin/+ (Min) mice (5-6
weeks of age) for Studies III (Experiment 1) and IV were obtained from Jackson
Laboratory,  ME,  USA.  The  Min  pedigree  was  maintained  at  the  Laboratory  Animal
Centre, University of Helsinki, by mating wild-type C57BL/6J females with Min
males originally obtained from Jackson Laboratory. Offspring were genotyped after
weaning by using Promega’s Wizard® Genomic DNA Purification Kit followed by
allele-specific polymerase chain reaction (Dietrich et al. 1993). Male and female Min
mice aged  5-6 weeks were used for Studies I-III (Experiment 2) and Study V, and
their wild-type siblings were also used in Study I. Mice were assigned randomly to
the experimental diets and housed in plastic cages, with a controlled room
temperature (20-22oC) and a 12-h light-dark cycle. They had free access to the
experimental diets and tap water. The body weights of the animals were recorded
weekly. If mice had a rapid decrease in weight or a prolapse of the rectum, they were
excluded from the experiment.
3.4 Analytical methods
3.4.1 Tumour scoring and sample collection
At the end of the feeding periods, mice were killed by carbon dioxide asphyxiation at
the age of 11-12 weeks (I, III, IV) or 15 weeks (II, V). A blood sample was collected
from the abdominal aorta and centrifuged at 6000 x g for  1  min,  after  which  the
plasma  was  stored  at  -70oC for enterolactone analyses. At autopsy, the uterus was
excised and weighed (V). The small intestine and colon were removed and cut open
longitudinally, and the contents of the small intestine and caecum were collected and
stored at -70oC for lignan analysis (I, II) and Bifidobacterium analysis (III). The
intestinal tissues were washed with ice-cold saline, and scoring of adenomas was done
as described by Mutanen et al. (2000). Briefly, the small intestine and colon + caecum
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were rinsed after they were spread flat, mucosal surface up, on a microscope slide.
The number, diameter and location of adenomas were determined with a dissection
microscope with a magnification of 67 x by two observers blind to the dietary
treatment. The minimum detection limit of the adenoma diameter was 0.3 mm.
Adenoma tissue was clipped off, and the small intestinal mucosa was scraped. Tissues
were snap-frozen in liquid nitrogen and stored at -70oC for further analysis.
3.4.2 b-Catenin, COX-2 and PKC protein analysis by Western blot
Subcellular localization of b-catenin and PKC is considered to be an important
determinant of their function. The mucosa and adenoma tissues of the small intestine
were therefore fractionated into nuclear, cytosolic and membranous fractions as
described by Pajari et al. (1998, 2003) for Western blot analysis. Normalized amounts
of the fractionated proteins and controls for inter-assay variation were resolved by
sodium dodecyl sulphate – polyacryl amide gel electrophoresis, and blotted onto
membranes capable of binding proteins. Signals of specific proteins were visualized
by using primary and secondary antibodies as described in Studies II and IV. Blots
were scanned and analysed, and results in duplicate were expressed as sample band
intensity (optical density of the band multiplied by the band area) divided by control
band intensity.
3.4.3 Lignan analysis
In Studies I-III, Professor Herman Adlercreutz’s group (University of Helsinki,
Finland) carried out lignan analysis of tissue samples, brans and diets. Plasma
enterolactone was analysed by using time-resolved fluoroimmunoassay (Adlercreutz
et al. 1998, Stumpf et al. 2000b), and lignans (enterodiol, enterolactone, and
secoisolariciresinol) of the small intestine and caecal contents were measured by
using HPLC with coulometric electrode array detector (Mazur et al. 1996, Nurmi &
Adlercreutz 1999). Lignans (lariciresinol, matairesinol, pinoresinol,
secoisolariciresinol and syringaresinol) of brans and diets were analysed by using gas
chromatography-mass spectrometry (Mazur et al. 1996, modified by Nurmi,
Heinonen and Adlercreutz, unpublished results). In Study V, the plasma lignans
(cyclolariciresinol, enterodiol, enterolactone, 7-hydroxyenterolactone, 7-
hydroxymatairesinol (both diastereomers), lariciresinol, matairesinol and
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secoisolariciresinol) were analysed by Associate Professor Rainer Sjöholm’s group
(Åbo University, Finland) by using HPLC-tandem mass spectrometry. Due to the
analysis procedure, the value of each lignan represents the sum of all conjugated and
unconjugated forms of this particular lignan.
3.4.4 Bifidobacterium analysis
Dr. Jaana Mättö (VTT Biotechnology, Finland) carried out Bifidobacterium analysis
as described in Study III. Bifidobacteria were enumerated from the samples by
culturing on bifidobacteria-selective agar and identified by colony and microscopic
morphology and simple phenotypic tests. The detection limit was 104 colony-forming
units/g wet weight.
3.4.5 Fatty acid analysis
In Study II, Irma Salminen (National Public Health Institute, Finland) carried out fatty
acid analysis of the colonic mucosa tissue by using gas chromatography. Values for
fatty acids are expressed as a percentage of total fatty acids.
3.5 Statistical analysis
Data were analysed either with the non-parametric Kruskal-Wallis test followed by
the  Mann-Whitney  U-test  (IV)  or  with  the  Mann-Whitney  U-test  alone  to  compare
experimental groups with the control group, and genders within a diet group (I-III,V).
Associations between variables were analysed with the non-parametric Spearman’s
correlation test (I, II). Colon adenoma number was evaluated with by c2 test, and two-
way analysis of variance (general linear model) was used to test normally distributed
plasma enterolactone data for diet x gender and diet x genotype interactions in Study
I. Distributions of two variables were analysed with the Wilcoxon signed-ranks test
(II). Statistical analyses were performed with SPSS software, version 6.1-10.0 (SPSS
Inc., Chicago, IL) or Stat View software, version 5.0.1 (SAS Institute Inc., Cary, NC).
Differences were considered significant at P < 0.05.
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4 Results and discussion
4.1 General observations
In our experience, weight gain of a Min mouse during the feeding period is an
indicator of a mouse’s health, and a decrease in weight at the end of the feeding
period is usually associated with a high tumour load. The weight gain and final body
weights did not differ between dietary groups in Studies I, II (females) and III-V. In
Study II the Min males fed the flaxseed diet had a significantly higher body weight at
the end of the 10-week feeding period than control males (P < 0.05). Visual
evaluation of mice during the feeding period revealed that 50% of animals in the 7-
hydroxymatairesinol group had some shedding of hair, which might indicate that the
level of 7-hydroxymatairesinol extract in the diet or its composition had some
unwanted effects. When matairesinol and secoisolariciresinol were fed to mice (Study
V), no such effect on fur was observed.
4.2 Adenoma number and size
The first aim of this project was to determine whether lignan-rich diets affect
intestinal tumour formation in Min mice. The adenoma results from all studies are
summarized in Table 5. The end-points were the number and size of tumours in the
small intestine and colon, and the incidence of colon adenomas (the number of
tumour-bearing animals). The range of adenoma number and adenoma distribution
between the small intestine and the colon here were similar to those found in other
studies (Moser et al. 1990, Corpet & Pierre 2003).
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Table 5. Effects of experimental diets on adenoma number and size of multiple intestinal neoplasia (Min) mice in Studies I-V.
Small intestine Colon and caecum
Study Diets n Number1 Size (mm)1  Incidence  (%)2 Number1 Size (mm) 1
I Non-fibre 12 ?
13 ?
57 ± 30
57 ± 27
1.0 ± 0.2
0.9 ± 0.1
 7/12          (58)
8/13          (62)
1.2 ± 1.1
0.7 ± 0.6
2.7 ± 0.7
2.0 ± 0.6
Defatted flaxseed 17 ?
16 ?
46 ± 17
56 ± 27
1.0 ± 0.2
0.9 ± 0.1
 9/17          (53)
5/16          (31)
0.8 ± 0.9
0.4 ± 0.6
2.5 ± 0.7
2.4 ± 0.7
II Non-fibre 14 (total)
8 ?
6 ?
54 (31, 86) 1.2 (0.9, 1.3)
4/8            (50)
0/6             (0)
0.5 (0, 3)
  -
2.9 (2.6, 3.1)
-
Flaxseed mixture 11 (total)
6 ?
5 ?
37 (13, 81) * 0.9 (0.8, 1.2) *
3/6            (50)
1/5            (20)
0.5 (0, 2)
0 (0, 2)
3.5 (3.3, 3.8) *
3.3 (3.3, 3.3)
Oil mixture 11 (total)
6 ?
5 ?
42 (15, 90) § 1.0 (0.7, 1.4) *
 2/6           (33)
 2/5           (40)
0.5 (0, 3)
0 (0, 2)
3.0 (2.8, 3.3)
1.7 (1.1, 2.3)
III 3 Non-fibre 21 ??? 31 ± 11 1.2 ± 0.2  7/21          (33) 0.5 ± 0.9 2.7 ± 0.8
Rye bran 23 ??? 42 ± 25 1.2 ± 0.2  15/23 *     (65) 1.3 ± 1.5 * 2.7 ± 0.8
Soluble extract 23 ??? 44 ± 23 ‡ 1.4 ± 0.2  16/23 *     (70) 1.0 ± 1.0 * 2.8 ± 1.0
Insoluble extract 12 ? 38 ± 14 1.3 ± 0.2  8/12          (67) 0.9 ± 0.9 2.9 ± 1.1
IV Inulin 8 ? 40 ± 9 1.2 ± 0.1  6/8            (75) 1.3 ± 1.1 1.0 ± 0.7
Inulin + Rye bran 7 ? 36 ± 7 1.2 ± 0.2  4/7            (57) 0.9 ± 0.9 1.2 ± 1.2
Inulin + 7-hydroxymatairesinol extract  8 ? 27± 11 * 1.1 ± 0.2  6/8            (75) 1.3 ± 1.1 1.1 ± 0.8
V Non-fibre 26 ??? 51 ± 27 1.2 ± 0.2  13/26        (50) 0.5 ± 0.1 3.0 ± 0.8
Matairesinol 11 ??? 67 ± 25 † 1.4 ± 0.2 *  4/11          (36) 0.4 ± 0.5 2.9 ± 1.1
Secoisolariciresinol 13 ??? 54± 28 1.2 ± 0.2  3/13          (23)  0.4 ± 0.9 2.4 ± 0.8
1 Values are mean ± SD or median (min, max). * Significantly different (P < 0.05) compared with the control group; § P = 0.095; ‡ P = 0.063; † P = 0.052.
2 The number of animals (%) bearing tumours in the colon and caecum.
3 Data of the pooled results of experiments 1 and 2 are presented in Study III. See the original publication for further details.
45
In Studies I and II, Min mice were fed diets containing either low or high levels of
flaxseed, providing mainly secoisolariciresinol diglycoside at levels of 73 and 380
mmol per kg diet, respectively. A diet with a low amount of flaxseed (Study I) had no
effect on adenoma number and size in the small intestine. Nor was there any change
between diet groups in adenoma number, size, incidence or distribution in the colon,
although the flaxseed-fed males and females had a non-significant tendency for a
decreased adenoma number in the colon. In the subsequent flaxseed study (II), the
flaxseed mixture rich in lignans and a-linolenic acid decreased the number of
adenomas in the small intestine by 31% (P <  0.05).  The  adenoma  size  of  the  small
intestine was also decreased in the flaxseed mixture group and in the oil group (both P
< 0.05). The males of the flaxseed mixture group had an increased adenoma size in the
colon (P < 0.05). Otherwise, the incidence, number and size of the colon adenomas
were not different between control and treatment groups.
In Study III, diets supplemented with rye bran and rye fractions contained mainly
syringaresinol plus other lignans at levels between 7 and 21 mmol  per  kg  diet.  The
pooled results of Experiments 1 and 2 showed that the soluble extract increased (albeit
not significantly) the number of adenomas in the small intestine (P = 0.063). The major
differences between the experimental groups were found in the distal small intestine,
where most of the adenomas were situated (see detailed results in the original
publication). The rye-bran and the soluble-extract groups (P = 0.032-0.037) had
significantly more colon adenomas than the non-fibre control group. The size of the
colon adenomas was not significantly altered between the experimental groups. The
colon adenoma number of the rye-bran group might be a chance result since no
difference in colon adenoma number was found between the rye-bran (10%) and non-
fibre control groups in our previous study (Mutanen et al. 2000). The effect of rye bran
on adenoma formation was also neutral in Study IV. In this study, the mice fed the diet
supplemented with inulin + rye bran had a similar adenoma number and size to mice
fed the inulin (control) diet.
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Crude 7-hydroxymatairesinol extract, and pure matairesinol and secoisolariciresinol
preparations were used in Studies IV and V, providing lignans at levels of 260 and 560
mmol per kg diet, respectively. The diet supplemented with the 7-hydroxymatairesinol
extract decreased the number of adenomas in the small intestine by 33% (P < 0.05)
compared with the control group. The matairesinol-fed mice had an increased adenoma
size (P < 0.05) in the small intestine, whereas secoisolariciresinol had no effect on
adenoma formation in the small intestine. The colon adenoma parameters did not differ
between groups in Studies IV and V.
Do lignan-rich diets have an effect on intestinal adenoma formation in Min mice when
adenoma number and size are the end-points? The results of Studies I-V do not give an
unequivocal answer to this question. Defatted flaxseed at moderate levels was not
protective against intestinal adenoma formation in Study I. In the subsequent flaxseed
study, the oil diet inhibited intestinal adenoma growth nearly as effectively (P < 0.05)
as the flaxseed mixture diet, suggesting that the oil component was mainly responsible
for the antitumour effect of the flaxseed diet and not the lignans per se. In Study III, the
soluble extract, which was partly hydrolysed and easily fermentable, contained a large
amount of mammalian lignan precursors, supported the growth of Bifidobacterium and
promoted adenoma growth in Min mice. Adenoma sizes of the non-fibre (lignan-free)
and rye-bran groups were, however, smaller than that of the soluble-extract group. The
effects of these rye preparations on adenoma formation thus appeared not to be
mediated through lignans. In Studies IV and V, pure lignan isolates were used, and
therefore, changes in tumour formation in Min mice could be related directly to lignans.
The effect of 0.02% secoisolariciresinol was neutral with regard to adenoma formation
in the small intestine and colon. However, it is interesting that both flaxseed (diet
providing secoisolariciresinol diglycoside) and secoisolariciresinol groups had a
tendency for decreased adenoma number and incidence in the colon in Studies I and V.
At present, we do not have an explanation for this observation, nor is it easy to confirm
since a low colonic adenoma number is not an ideal end-point marker in Min mice.
The chemical structures of 7-hydroxymatairesinol and matairesinol differ only by one
hydroxyl group. However, discordant effects on adenoma formation in Min mice were
found after 7-hydroxymatairesinol and matairesinol feedings. The diet supplemented
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with the 7-hydroxymatairesinol extract inhibited and that with matairesinol promoted
tumour formation in the small intestine. This controversy may be due to different
experimental designs, including composition of experimental diets, or it may partly
reflect true differences in effects of these lignans. The control diet in Study I was 2.5%
inulin, which was used to promote adenoma formation, and not the non-fibre diet used
in Studies II-V. Differences in the chemical structure of pure compounds might also be
highly important with regard to lignan metabolism and chemoprevention. Saarinen et
al. (2002b) reported that the urinary excretion of enterolactone in rats was greater in the
matairesinol group than in the 7-hydroxymatairesinol group after a single oral dose of
aglycone lignans (25 mg/kg per kg body weight). The authors suggested that the
presence of the hydroxyl group at carbon atom number 7 in the 7-hydroxymatairesinol
molecule slowed down the formation of enterolactone, resulting in a higher level of 7-
hydroxymatairesinol inside the gut lumen. Saarinen et al. (2005) reported also that
nortrachelogenin which resembles 7-hydroxymatairesinol, but has a hydroxyl group at
C-8 instead of C-7, was not enterolactone precursor in vivo. Furthermore, 7-
hydroxymatairesinol but not nortrachelogenin has been shown to inhibit the growth of
mammary tumours in carcinogen-treated rats (Saarinen et al. 2000, 2001). In our study,
the 7-hydroxymatairesinol extract also contained other lignans, which might together
affect adenoma formation.
Due to the limited availability of purified lignans, only a few studies have attempted to
elucidate the role of lignans in animal models for colon cancer.  Jenab and Thompson
(1996) and Hirose et al. (2000) have shown protective effects of secoisolariciresinol
and arctiin on early precancerous lesions in carcinogen-treated rats. Recently, van
Kranen et al. (2003) reported a study where Min mice were fed 5% flaxseed or 30%
rye-bran diets, which provided flaxseed and rye-bran lignans of 140 mg and 0.6 mg per
kg diet, respectively. The authors reported that neither 5% flaxseed nor 30% rye-bran
diets were able to decrease intestinal adenoma formation; in fact, female Min mice fed
a 30% rye-bran diet had an increased number of small intestinal adenomas.
In conclusion, the current experimental evidence regarding the role of lignans in colon
neoplasia is limited and shows conflicting results. Our findings as well as those of van
Kranen et al. (2003) do not support the assumption that flaxseed and rye diets providing
such lignans as secoisolariciresinol or syringaresinol would exert an anticarcinogenic
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effect in Min mice. Secoisolariciresinol administered as a pure compound at a level
0.02% (w/w) also failed to show a chemopreventive effect. The effects of matairesinol
and 7-hydroxymatairesinol on adenoma formation in Min mice were conflicting and
should be clarified in further studies.
4.3 Mammalian lignan levels in the plasma
Our results showed that plasma enterolactone or enterodiol levels did not explain
adenoma formation in Min mice. We can not state that a high mammalian lignan level
is necessary for colon cancer chemoprevention, and the oil diet without lignans was
protective against adenoma growth in this mice model. Our findings are in line with a
study of human subjects, in which plasma enterolactone level was not found to be
associated with colorectal cancer risk (Lundin 2001). However, experimental and
human studies have shown that the role of plasma enterolactone in other types of
cancer, e.g. mammary cancer, may be more prominent. The plasma lignan results are
therefore discussed in an attempt to shed light on lignan metabolism in vivo.
The plasma enterolactone levels of Min mice fed the experimental diets are summarized
in Figure  4. The order of enterolactone production between dietary groups was as
follows: matairesinol group (median 203 nmol/l) > secoisolariciresinol group (median
85 nmol/l) » flaxseed mixture group (median 97 nmol/l) > 0.5% flaxseed group
(median 47 nmol/l) > 10% rye-bran group (median 32 nmol/l) > 7.9% soluble-extract
group (median 15 nmol/l) > non-fibre control and oil groups (median < 10 nmol/l). All
lignan-supplemented groups had significantly higher levels of plasma enterolactone(P <
0.05) than the control groups. Flaxseed and rapeseed oils in the oil diet were not
sources of plant lignans, and thus, intestinal or plasma lignan levels of the oil group did
not differ from the control group. Overall, rye-diet-fed mice were lower enterolactone
producers than flaxseed- or wood-lignan-fed mice. Rye bran is a source of other plant
lignans, such as lariciresinol, pinoresinol and syringaresinol, in addition to matairesinol
and  secoisolariciresinol,  which  are  the  two  lignans  known  to  metabolize  to
enterolactone and enterodiol in vivo. The in vitro conversion of lariciresinol,
pinoresinol and syringaresinol to both enterodiol and enterolactone has been reported
(Heinonen et al. 2001).
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Figure 4. Plasma enterolactone levels (nmol/l) of multiple intestinal neoplasia (Min)
mice fed the experimental diets in Studies I-III and V. For each group, the box
represents the interquartile range, which contains 50% of values. The whiskers
(vertical lines) extend from the box to the highest and lowest value. Horizontal lines
across the boxes indicate medians. Outliers (?) are cases with values between 1.5 and
3 box-lengths from the upper or lower edge of the box, and extremes (*) are values
more than 3 box-lengths from the upper or lower edge of the box. # An extreme
enterolactone value (975 nmol/l) in the matairesinol group was excluded from the
figure to make box-plots more understandable. ‡ The box represents the pooled plasma
enterolactone values of all non-fibre control groups analysed by time-resolved
radioimmunoassay. † The box represents those plasma enterolactone values analysed
by high-performance liquid chromatography-tandem mass spectrometry.
Diet groups
Matairesinol #
Secoisolariciresinol
Flaxseed mixture
Flaxseed 0.5%
Rye bran 10%
Soluble extract 7.9%
Oil
Non-fibre ‡
Non-fibre †
Plasma enterolactone (nmol/l)
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A large inter-individual variation in plasma enterolactone was found within the dietary
groups. This variation was largest in the matairesinol and secoisolariciresinol groups.
The reason for this is unclear. Similarly, a large inter-individual variation in serum
lignan levels has been found in experimental animals and in human subjects consuming
their habitual diets (Kilkkinen et al. 2001, Saarinen et al. 2001, Johnsen et al. 2004).
Because no reference was available in the literature, we also examined whether gender
or genotype differences are present in lignan metabolism in mice. We found that plasma
enterolactone did not differ between wild type and Min mice in Study I or between
genders in Studies II-V with the exception of secoisolariciresinol-fed mice: the plasma
enterolactone level was lower in males (49 nmol, n = 6) than in females (224 nmol, n =
6, P = 0.010) fed the same diet. This result may, however, be a chance result.
In Study V, nine different lignans were analysed in plasma of the Min mice. The
plasma matairesinol, secoisolariciresinol, enterodiol and enterolactone levels of mice
fed the experimental diets are summarized in Figure  5.   Levels  of  7-
hydroxymatairesinol (both diastereomers), 7-hydroxyenterolactone, lariciresinol and
cyclolariciresinol were near or below detection limits in most mice, and therefore, the
data are not shown. Both matairesinol and secoisolariciresinol were efficiently
absorbed. This is in line with other studies (Saarinen et al. 2001, 2002b, Smeds et al.
2004) reporting that the plant lignan 7-hydroxyenterolactone can be found in the serum
of 7-hydroxyenterolactone-fed rats, and that both a single oral dose and a ten-day
administration of secoisolariciresinol and matairesinol results in considerable excretion
of secoisolariciresinol and matairesinol in urine. The levels of plant lignans in the
plasma of matairesinol- and secoisolariciresinol-fed mice were surprisingly high
(medians over 200 nmol/l), which presents the possibility that plant lignans, at least in
the case of matairesinol, have an independent effect on tumorigenesis.
The plasma enterolactone levels did not directly reflect lignan levels in diets. Although
a fivefold difference was present in the dietary levels of defatted flaxseed between the
two flaxseed studies, only a twofold difference was found in plasma enterolactone
levels. The level of flaxseed in the second study may have exceeded the capacity of
microflora to metabolize lignans. Similarly, the results of the rye study indicated that
the plasma enterolactone levels did not directly reflect the analysed lignan contents of
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Figure 5. Plasma matairesinol (A), secoisolariciresinol (B), enterodiol (C) and
enterolactone (D) levels (nmol/l) of male and females multiple intestinal neoplasia
(Min) mice fed the experimental diets in Study V. For each group, the box represents
the interquartile range, which contains 50% of values. The whiskers (vertical lines)
extend from the box to the highest and lowest value. Horizontal lines indicate
medians across the boxes. Outliers (?) are cases with values between 1.5 and 3 box-
lengths from the upper or lower edge of the box, and extremes (*) are values more
than 3 box-lengths from the upper or lower edge of the box.
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the rye diets. Based on the lignan analysis, the soluble-extract diet contained more
lignans than the rye-bran diet. Mean plasma enterolactone was, however, highest in the
rye-bran group (mean 30 nmol/l), and not the soluble-extract group (16 nmol/l). The
ray-bran matrix may be more resistant to analytical hydrolysis than the soluble fraction,
but may be degraded extensively inside the colon, thus freeing bound lignan for
metabolism and absorption. In addition, slowly fermentable rye bran may be more
susceptible to enterolactone formation than the fermentable soluble extract. Intestinal
microflora adaptation to the experimental diets could also lead to differences in plasma
enterolactone levels.
Rickard et al. (2000) have reported that flaxseed and/or secoisolariciresinol reduced
plasma concentration of insulin-like growth factor (IGF)-1 in rats treated with or
without N-methyl-N-nitrosourea carcinogen. The authors suggested that the anticancer
effect of flaxseed and lignans may be related, in part, to the reduction of plasma IGF-1
level, with the major target organ for lignan action suggested to be the liver, which also
regulates the synthesis of IGFs and IGF-binding proteins. Interested readers are referred
to Pollak et al. (2004), who recently reviewed the role of the IGF-1 signalling pathway
in cellular proliferation, survival and apoptosis. To test this hypothesis between lignans
and plasma IGF-1 levels, we analysed the plasma IGF-1 levels of mice fed control,
flaxseed and oil diets in Study II. Plasma samples were treated and IGF-1 levels were
analysed by radioimmunoassay according to manufacturer’s instructions (rat IGF-1
RIA, Diagnostic Systems Laboratories, Inc., Webster, Tx). We found no significant
differences  in  plasma  IGF-1  levels  between  the  dietary  groups.  The  plasma  IGF-1
levels (ng/ml) were 498 ± 108, 557 ± 74 and 520 ± 111 (mean ± SD) for the control,
flaxseed and oil groups, respectively (unpublished results). That the plasma IGF-1
levels of the flaxseed and oil groups appeared to be slightly elevated compared with the
control group, but these values did not reach statistical significance (P = 0.189 and P =
0.584 for flaxseed and oil groups, respectively). Thus, our preliminary result with IGF-
1 does not support the suggestion that plasma IGF-1 has a role in prevention of
adenomas in Min mice.
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4.4 Mammalian lignan production inside the intestinal lumen
Mammalian lignan formation or secoisolariciresinol level did not explain adenoma
number or size in Min mice, although substantial levels of lignans were present in the
lumen. Interestingly, the Min males fed the flaxseed diets had a higher level of
intestinal enterolactone than the Min females fed the same diet. In addition, wild-type
mice fed the flaxseed diet had a gender difference in caecal enterolactone levels. The
reason for this is unclear, and no comparable studies exist in the literature. Bacterial
bioconversion of the plant lignan secoisolariciresinol to the mammalian lignans or
enterohepatic circulation of enterolactone might be different between male and female
mice.  Further  study  of  lignan  metabolism  is  thus  warranted.  We  also  found  that  Min
genotype or phenotype by some unknown mechanism influences intestinal lignan
metabolism. Min mice had less intestinal enterodiol and enterolactone than their wild-
type littermates. However, the responses to diets were similar in both genotypes. One
explanation for these results may be that bleeding from the intestinal adenomas changes
levels or populations of microorganisms or bacterial enzyme activities, thus modifying
dietary lignan metabolism. We also found that plasma enterolactone levels do not
reflect gender or genotype differences in gut enterolactone.
4.5 Effects of other dietary components in flaxseed and rye fractions on adenoma
formation in Min mice
4.5.1 Fatty acids
The type of fat has been suggested to affect colonic neoplasia in experimental animals
and human subjects (Hansen Petrik et al. 2000, Davidson et al. 2004, Roynette et al.
2004). Particularly, the roles of n-3 and n-6 polyunsaturated fatty acids (PUFAs) on
colon  tumorigenesis  have  been  studied  extensively.  In  general,  n-3  PUFAs (from fish
oil) have been proposed to act as tumour preventive agents in colon cancer experiments.
The proposed underlying mechanisms by which these fatty acids might exert their
effect on colonic neoplasia include alteration of membrane phospholipid turnover and
prostaglandin synthesis (Rao et al. 1996), downregulation of protein kinase C bII
activity (Murray et al. 2002) and anti-apoptotic Blc-2 protein level (Hong et al. 2003)
and increased apoptosis of colonic cells (Davidson et al. 2004).
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The role of another n-3 PUFA, namely a-linolenic acid (18:3n-3), in chemoprevention
was evaluated in Study II. The control diet contained (g/kg diet) 24 g of linoleic acid,
whereas the values of a-linolenic acid were 37-39 g in both flaxseed and oil diets. Both
flaxseed and oil diets similarly changed the colonic fatty acid profile, a marker for fatty
acid  intake  (see  Table  4  in  Study  II).  Changes  in  proportions  of  PUFAs  also  led  to
changes in the ratio of n-6 to n-3 PUFAs, which were 1.6:1 (P < 0.001) and 1.7:1 (P <
0.001) for the flaxseed and oil groups, respectively, and 4.4:1 for the control group.
Thus, the effect of oil may be due to a direct effect of a-linolenic acid or changes in the
ratio of n-6 to n-3 fatty acids of the intestinal mucosa. a-Linolenic acid has been
reported to decrease tumour or ACF formation in some but not all studies of colon
cancer (Narisawa et al. 1994, Onogi et al. 1996, Hansen Petrik et al. 2000, Dwivedi et
al. 2005). Furthermore, the oil component of flaxseed was considered less important
than lignans as an effective agent by Serraino and Thompson (1992) and Jenab and
Thompson (1996).
COXs, the key enzymes in regulating the synthesis of such prostaglandins as
prostaglandin E2 (PGE2), have been suggested to be responsible for cancer-promoting
effects in humans and animals. Wang et al. (2005) recently demonstrated that PGE2 can
enhance intestinal proliferation and COX-2 expression in adenomas of Min mice
through a positive feedback loop. Furthermore, the authors reported that activation of a
Ras-mitogen-activated protein kinase (MAPK) signalling cascade was required for PGE
to induce COX-2 expression. Hansen Petrik et al. (2000) have similarly shown that the
antitumorigenic effect of n-3 eicosapentaenoic acid (EPA) on adenoma formation in
Min mice was related in part to alterations in prostaglandin biosynthesis and a
decreased level of PGE2 in the intestinal tissue. However, the synthesis of
prostaglandins is also dependent on n-6 and n-3 chain PUFAs such that n-3 long-chain
PUFAs can displace arachidonic acid, and eicosanoids derived from n-3 long-chain
PUFAs oppose the action of those derived from n-6 fatty acids. Unfortunately, because
we  did  not  measure  the  PGE2 level in intestinal tissues due to the lack of intestinal
samples, the role of PGE2 in Study II remains obscure.
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Increased COX-2 expression favours colonic neoplasia, and non-steroidal anti-
inflammatory drugs acting as COX inhibitors play an important role in cancer
prevention (Gupta & Dubois 2001). In Study II, we analysed COX-2 expression in
adenomas to determine whether this could explain the inhibition of adenoma growth
found in the flaxseed and oil groups relative to the control group. We found that the
COX-2  protein  level  was  not  dependent  on  diets,  although  a  positive  correlation  was
present between COX-2 level and adenoma growth (r = 0.536, P = 0.001, n = 33).
Unfortunately, we did not measure COX-2 activity, which might also be modulated by
the experimental diets. In another study, the administration of 1,4-phenylene
bis(methylene) selenocyanate decreased adenoma number in Min mice, and also
lowered COX-2 activity in adenomas, while leaving the level of COX-2 protein
unchanged (Rao et al. 2000).
Boolbol et al. (1996) and  Mahmoud et al. (1997) reported that enterocyte apoptosis
and migration upwards to the apex of the villus were decreased by 27-47% and 25%,
respectively, and cell proliferation was decreased by 45% in the normal-appearing
mucosa of Min mice as compared with wild-type mice. Tumour prevention by plant
phenolics, caffeic acid phenethyl ester and curcumin, have later been shown to be
associated with increased levels of enterocyte apoptosis and proliferation (Mahmoud et
al. 2000). Recently, Davidson et al. (2004)  reported  that  fish  oil  (n-3  PUFA) feeding
increased the level of apoptosis in the upper part of colonic crypts compared with corn
oil (n-6 PUFA) and olive oil (n-9 monounsaturated fatty acids) treatments.
Furthermore, microarray analysis of colonocyte expression profiles showed that fish oil
up-regulated genes involved in apoptosis and differentiation. Thus, changes at the
cellular level of apoptosis may be the key in cancer prevention. To determine whether
the experimental groups in Study II would experience a change in the level of
enterocyte apoptosis, we analysed the number of cytoplasmic histone-associated DNA
fragments by an assay based on a quantitative sandwich-enzyme immunoassay (Cell
Death Detection ELISAPLUS, Roche Diagnostics GmbH, Mannheim, Germany). In this
assay, the histone-associated DNA fragments indicate DNA degradation of apoptotic
cells. The measuring of apoptosis was carried out according to manufacturer’s
instructions, and the absorbance values of control (1.0 ± 0.9, mean ± SD, n =  6),
flaxseed (1.1 ± 1.0, n = 6) and oil (1.5 ± 0.5, n = 6) groups were standardized to the
corresponding values obtained from wild-type mice fed the control diet (1.2 ± 1.0, n =
56
6) (unpublished results). When the relative level of enterocyte apoptosis was set to
100% for wild-type mice, the respective values for control-, flaxseed-, and oil-diet-fed
Min  mice  were  83%  (P = 0.873), 97% (P = 1.000) and 130% (P = 0.263). These
preliminary results showed that the flaxseed and oil groups had a non-significant
tendency for an increased level of apoptosis in the intestinal mucosa, which might be
associated with lowered tumour load and smaller tumour size in these experimental
groups.
In summary, the results suggest that the oil component of flaxseed and rapeseed oils has
a chemopreventive effect on adenoma formation, especially with regard to adenoma
growth in Min mice. The exact mechanism for prevention remains unclear, but it may
be related to a-linolenic acid and perhaps diet-induced changes in cellular apoptosis.
The results of this experiment warrant further investigation.
4.5.2 Fibre
In Study II, the flaxseed diet also contained wheat fibre, which consists mainly of
cellulose and hemicellulose isolated from wheat bran. Several studies have shown that
wheat bran is protective against colon cancer in carcinogen-treated rats (McIntry et al.
1993, Zoran et al. 1997, Jenab & Thompson 1998). In Min mice, 5-10% wheat bran or
cellulose supplementation inhibited adenoma formation in the small intestine but not in
the colon compared with a high-fat, non-fibre diet (Yu et al. 2001). ApcD716 mice fed a
low-risk  diet  (20%  wheat  bran  and  5%  fat)  were  observed  to  have  less  polyps  in  the
small intestine and the colon than their peers receiving a high-risk diet (2×5% wheat
bran and 20% fat) (Hioki et al. 1997). However, this study did not separate the effects
of fat and fibre on adenoma formation. In our previous study, we found that adenoma
number in the small intestine and colon of a high-fat wheat bran (10% w/w) group or a
low-fat AIN-93G (contains 5% cellulose) group was not different from that of a high-
fat non-fibre group (Mutanen et al. 2000). Therefore, while the effect of wheat fibre in
Study II is somewhat unclear, wheat fibre may confer some protective effect against
adenoma formation.
We conducted Study III to determine whether fractionation of rye bran increases its
anticarcinogenic properties, which might be related to bifidogenicity and lignans. We
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found that the rye fraction, refer to here as the soluble extract, actually promoted
adenoma growth in Min mice, whereas rye bran and insoluble-fraction had neutral
effects. All rye diets had equal levels of fibre (4%), and therefore, the amount of rye
fibre as such does not explain adenoma growth. The fractionation of rye bran was based
on water solubility, and it was highly fermentable in vitro (Karppinen et al. 2001).
Although the fermentability of the soluble-extract was not proven to be the reason for
the enhanced growth pattern of adenomas, our other studies with highly fermentable
inulin fibre, which increased adenoma number and size in Min mice, support this
interpretation (Mutanen et al. 2000, Pajari et al. 2003). The results of our studies with
Min mice consistent with earlier research which has shown that soluble fibres, e.g. oat
bran, pectin and guar gum, increase the number and incidence of colonic tumours in
carcinogen-treated rats (Jacobs & Lupton 1986, McIntry et al. 1993, Zoran et al. 1997).
The role of fibres in adenoma formation in Min mice is sometimes questioned since
most of the adenoma formation occurs in the small intestine, whereas the colon is the
main site for bacterial fermentation of fibres. It has, however, been shown that gut
fermentation (via SCFA and small enteropeptides) increases epithelial cell proliferation
in both the large and the small intestine (Goodlad et al. 1995, Sakata 1995). The
presence of adenomas, mainly in the distal small intestine, may also affect the flow of
digesta, which in turn could influence colonization of microbes and microbe
metabolism in this area.
Fibre stimulates bacterial growth, increasing faecal bulk, and may cause alterations in
colonic microflora, e.g. changes in bacterial species and enzyme activities (Kim 2000).
Attempts to increase such bacterial groups as Bifidobacterium and Lactobacillus have
been considered beneficial to the host’s health (Salminen et al. 1998). The aim of Study
III was to determine whether bifidobacteria level had any effect on adenoma formation
in Min mice fed different rye preparations. The results revealed that processing of rye
bran  into  two  fractions  did  not  affect  bifidogenicity  of  the  substrate.  A  considerable
number (109 cfu/g) of Bifidobacterium were found in mice fed the standard chow prior
to the feeding experiments. Removal of fibre in the non-fibre diet decreased the level of
Bifidobacterium to below detection limits (less than 104 cfu/g). However, 6-7 weeks of
feeding with three different rye diets sustained Bifidobacterium at similar levels (108-
109 cfu/g). The results clearly show that water solubility does not affect bifidogenicity
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of rye bran; even the insoluble fraction sustained bifidobacteria growth, as has been
demonstrated for soluble preparations in vitro (Crittenden et al. 2002). The results
further show that the non-fibre group had a concomitant decrease in intestinal
Bifidobacterium level during the feeding period, yet did not have an increased number
of adenomas in the colon. Thus, growth of bifidobacteria in Min mice does not appear
to regulate colon adenoma formation. Pierre et al. (1997), on the other hand, showed
that short-chain fructo-oligosaccharides (sc-FOSs), used as a prebiotic substrate for
Bifidobacterium, decreased the number of colon adenomas. The authors concluded,
however, that T cells related to immunosurveillance, and not bifidogenicity, participate
in the mechanism of colon tumour initiation in Min mice fed sc-FOSs (Pierre et al.
1999). The role of prebiotics and/or probiotic bacteria in colon carcinogenesis has also
been studied by using carcinogen-treated rats (Arimochi et al. 1997, Challa et al. 1997,
Onoue et al. 1997, Reddy et al. 1997, Singh et al. 1997, Rowland et al. 1998, Femia et
al. 2002). The results of these studies are, however, inconsistent, indicating how strong
the influence of background diet, bacteria strain or prebiotic source can be.
In summary, the type of fibre may modulate adenoma formation in Min mice, although
the exact mechanism is unclear. Wheat fibre consisting mainly of cellulose may have
some additive chemopreventive effect, whereas highly fermentable fibres may enhance
intestinal tumour formation in Min mice. Bifidobacterium level does not appear to
explain adenoma formation in this animal model.
4.6 Effect of diets on signal transduction parameters in Min mice
4.6.1 b-Catenin
The improper regulation of cellular b-catenin pools is one of the driving forces in Apc-
induced colonic neoplasia (Henderson 2000). Diet has been shown to affect b-catenin
localization in cellular compartments in Min mice; a decreased tumour number was
associated with reduced b-catenin  staining  as  well  as   redistribution  of b-catenin to a
more “normal” localization mainly at the intracellular junctions (McEntee et al. 1999,
Schmelz et al. 2001, Pajari et al. 2003, Misikangas et al. 2005). Thus, to find the reason
for the decreased number of adenomas in mice fed flaxseed (Study II) and 7-
hydroxymatairesinol (Study IV), we analysed the subcellular localization of b-catenin
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in the mucosa and adenoma tissues. The levels of cellular b-catenin are summarized in
Table 6.
The only significant diet effect on subcellular b-catenin levels was observed in 7-
hydroxymatairesinol-fed mice in which the nuclear b-catenin level in the adenoma
tissue (0.41 ± 0.25, relative units) was decreased significantly compared with the
control group (3.15 ± 2.90, relative units, P = 0.003). Thus, the nuclear b-catenin levels
in the adenoma and in the surrounding mucosa tissues did not differ significantly from
each other in the 7-hydroxymatairesinol group (Table 6). In other groups, the nuclear b-
catenin level was significantly elevated in adenoma tissue compared with the
surrounding mucosa tissue (Table 6). This indicates the unsuccessful post-
transcriptional regulation of b-catenin in adenomas due to the loss of the wild-type Apc-
gene.   Interestingly,  we  found  that  cytosolic b-catenin in adenomas was significantly
increased compared with the same fraction in mucosa tissue in Study IV, but not in
Study II (Table 6). A plausible explanation for this can be found in study designs. In
Study IV, all diets contained 2.5% inulin as a non-lignan fibre source, which served as a
promoter of adenoma formation (Mutanen et al. 2000, Pajari et al. 2003). Pajari et al.
(2003) demonstrated that the promotion of tumour development was significantly
accompanied by the accumulation of cytosolic b-catenin in adenoma tissue.
Table 6. Differential expression of b-catenin in the mucosa and adenoma tissues of
mice fed the experimental diets in Studies II and IV. 1
Study II Study IV
Fraction Non-fibre Flaxseed Oil Inulin Inulin/
Rye bran
Inulin/HMR
Cytosol ns ns ns  Ad > Muc Ad > Muc Ad > Muc
Membrane ns Muc > Ad Muc > Ad ns ns ns
Nuclear Ad > Muc Ad > Muc Ad > Muc  Ad > Muc Ad > Muc ns
1 Abbreviations are as follows:
ns, non-significant difference between the mucosa and adenoma tissues in b-catenin expression.
Ad>Muc, b-catenin expression in the adenoma tissue significantly higher than that of the mucosa tissue:
P < 0.05 (Wilcoxon signed-ranks test).
Muc>Ad, b-catenin expression in the mucosa tissue significantly higher than that of the adenoma tissue:
P < 0.05 (Wilcoxon signed-ranks test).
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A reduced association between membranous E-cadherin and b-catenin has been found
in Min mice as compared with their wild-type littermates (Carothers et al. 2001).
Misikangas et al. (2005) reported that at five weeks of age Min mice had less
membranous E-cadherin and b-catenin in the mucosa than their wild-type littermates.
Inulin feeding, which increased the adenoma size, reduced the levels of E-cadherin and
b-catenin in the mucosal membranes in both Min and wild-type mice compared with
control groups (Misikangas et al. 2005). In Study II, there were no differences between
diet groups in membranous b-catenin measured in the adenoma tissue. However, in the
normal-appearing mucosa, membrane b-catenin levels were slightly elevated in the
flaxseed group relative to the control group (median 1.8 vs. 0.8, P = 0.09) (Figure 3 in
Study II). This might indicate a protective effect of defatted flaxseed, wheat fibre,
flaxseed and rapeseed oils on mucosal integrity, and thus, on intestinal adenoma
formation.
4.6.2 Protein kinase C-z
Protein kinase C (PKC) isozymes are involved in diverse biological processes,
including cellular proliferation, differentiation and apoptosis as well as malignant
transformation (Black 2001). Human and animal studies have shown that PKC-bII is
up-regulated, and PKC-a,  -bI,  -d and  -z are down-regulated in colon tumourigenesis
(Kahl-Reiner et al. 1994; Wali et al. 1995; Klein et al. 2000, Murray et al. 2002). Klein
et al. (2000) reported a reduced protein expression of PKC-a,  -bI,  and -z in adenoma
tissue  compared  with  adjacent  mucosal  tissue  of  Min  mice  by  using  an
immunohistochemistry method. Recently, atypical PKCs (z, and l/t) have been shown
to co-localize with Par-proteins at cell-cell contacts in epithelial cells, thus establishing
cell polarity, and also to phosphorylate GSK-3b and subsequently induce association of
Apc with microtubules (Etienne-Manneville & Hall, 2003a,b). We chose PKC-z of all
PKC isozymes for our studies because its localization in cell fractions can be modulated
by diet (Pajari et al. 2000), it is down-regulated during the cancer process (Klein et al.
2000), it mediates the effect of various anticarcinogenic substances (Roy et al. 1995,
Wali et al. 1995, 1996), and it has been shown to interact with the Apc pathway
(Etienne-Manneville & Hall 2003b).
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By Western blot analysis, we found that PKC-z expression (sum of 70-kDa and 75-kDa
bands) was lower in the membranes of adenoma tissue compared with the same fraction
in the normal-appearing mucosa without a major reduction in PKC-z levels in tissues
(Table  5  in  Study  II).  This  is  in  line  with  a  study  where  the  majority  of  PKC-d and
PKC-z were localized in the cytosolic fraction of AOM-induced tumours but not in the
normal mucosa (Davies & Johnson 2002). We also found that membrane PKC-z
expression in the mucosa tissue was inversely associated with the adenoma number in
the same area in Min mice (r = -0.460, P = 0.008, n =  32).  Our  results  suggest  that
membrane-associated PKC-z protects against cancer, although the mechanism is still
unknown. An in vitro experiment with Caco-2 cell has demonstrated that EGF-induced
PKC-z translocation to membranes is necessary for stabilization of the microtubule
skeleton and cell barrier function against oxidative injury (Banan et al. 2002).
Furthermore, through interaction with atypical PKC, the mammalian Par-proteins
regulate the formation of epithelial cell-cell junctions, which are essential for the
establishment of epithelial cell polarity (Etienne-Manneville & Hall 2003b). In normal
murine intestinal epithelium, PKC-z  was  detected  mainly  in  the  post-mitotic  cells  of
the upper crypt and surface mucosa, and in the membrane/cytoskeletal compartments
(Saxon et al. 1994; Verstovsek et al. 1998).  Therefore,  the  presence  of  PKC-z in the
membrane fraction of epithelial cells seems to be involved in the normal differentiation
and maturation processes.
In summary, the subcellular localization of b-catenin and PKC-z may exert an effect on
colonic neoplasia. PKC-z results showed that the diet might affect subcellular
localization of cell signalling molecules also in the normal-appearing mucosa.
However, the mechanism of action is complex and far from clear. The relevance of
subcellular localization of b-catenin and PKC-z in adenoma formation in Min mice
requires confirmation in future studies.
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4.7 Other results
No published data are available regarding gender differences in adenoma number in
Min mice (Moser et al. 1990). In Study I, however, we found that Min males had twice
as many adenomas in the colon (0.90 ± 0.94, mean ± SD, n = 29) as Min females (0.45
± 0.57, n = 29, P = 0.048). No gender difference was present in adenoma number in the
small intestine in the control and flaxseed groups. The gender difference in the colon
adenoma number in Min mice was unexpected, and no references were found in the
literature. To study this phenomena further, the adenoma data of all non-fibre control-
diet-fed male and female mice were collected in Studies I-V, and in studies conducted
by Pajari et al. (2003) and Päivärinta et al. (unpublished data). Altogether, 44 males and
44 females had been fed with the non-fibre diet until the age of 12-15 weeks. A pooled
data analysis supported the finding that colon adenoma number was significantly higher
in Min males than in Min females (0.8 ± 1.0, n = 44 vs. 0.4 ± 0.7, n = 44, P = 0.034,
Mann-Whitney U-test). The adenoma number in the small intestine, by contrast, did not
differ between the males and females fed the non-fibre diet (54 ± 23 vs. 55 ± 27, P =
0.940). The observation of a gender difference in colon adenoma number will suggest
that the underlying mechanism may be hormone-related. Indeed, studies of Weyant et
al. (2001) and Javid et al. (2005) have been shown that 17b-estradiol can modulate
intestinal tumour formation in ovariectomized Min mice. Our result and the adenoma
number in the colon being low question the suitability of using colon adenoma number
as an end-point marker for cancer prevention studies in Min mice. Research on a better
end-point marker for the colon is needed.
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5 Summary and conclusions
The effects of lignan-rich foods and pure lignans on intestinal tumorigenesis were
investigated using multiple intestinal neoplasia (Min) mice. We used flaxseed and rye
bran as lignan sources with different lignan profiles. Secoisolariciresinol is the primary
lignan in flaxseed, whereas mainly syringaresinol is found in rye bran and rye fractions.
Availability of pure lignan isolates, e.g. 7-hydroxymatairesinol from spruce, and
synthesis of other lignans, e.g. matairesinol and secoisolariciresinol, by using 7-
hydroxymatairesinol as a starting material enabled us to also evaluate the effect of pure
lignans on colon tumorigenesis. The main findings of Studies I-V may be summarized
as follows:
1. Flaxseed and rye diets providing such lignans as secoisolariciresinol diglycoside and
syringaresinol (I-III)  as well  as pure secoisolariciresinol supplementation (V)  showed
no anticarcinogenic effects in Min mice. The crude extract of 7-hydroxymatairesinol
had chemopreventive effects (IV), while pure matairesinol had tumour-promoting
effects in this mouse model (V). The underlying mechanisms by which these lignans
exerts opposite effects on tumorigenesis might, in part, be related to the direct actions
of these compounds.
2. Supplementation of the diet with lignan-rich components of flaxseed and rye-bran or
lignan preparations increased the levels of plant and mammalian lignans in both the
small intestine and the colon of Min mice, and also increased plasma enterolactone to
levels of 100 nmol/l or even higher. Studies with pure lignans showed that
enterolactone was the main plasma metabolite in matairesinol-fed mice, whereas both
enterolactone and enterodiol were found in the plasma of secoisolariciresinol-fed mice.
Substantial amounts of the lignan precursors matairesinol and secoisolariciresinol were
also  present  in  plasma  (I-III,  V).  We  found  also  that  gender  and  genotype  affect
enterolactone metabolism inside the gut lumen. Furthermore, plasma enterolactone
levels did not directly correlate with lignan levels found in the gut (I, II). However,
neither plasma enterolactone nor the intestinal enterodiol, enterolactone or
secoisolariciresinol levels were related to adenoma formation in the Min mouse model
(I-II, V).
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3. The lignan sources (flaxseed and rye bran) also provide other dietary components,
such as fat and fibre, which may affect tumorigenesis. The action of lignans should
therefore  not  be  stressed  over  other  possible  effective  agents.  The  oil  part  of  the
flaxseed mixture (rich in a-linolenic acid) was mainly responsible for inhibition of
intestinal  tumorigenesis,  particularly  with  regard  to  adenoma growth  (II). a-Linolenic
acid may directly or by changing in the ratio of n-6 to n-3 fatty acids of the intestinal
mucosa inhibit colon tumorigenesis. The type of fibre may also modulate adenoma
formation in Min mice, although the exact mechanism is unclear. Wheat fibre may have
had some additive chemopreventive effect (II). Fractionation of rye bran did not
increase its anticarcinogenic properties (III). If the fractionation of rye bran was based
on water solubility, and the rye fraction contained rapidly fermentable fibres, it was
slightly harmful in Min mice. Rye bran and fractions also sustained the growth of
Bifidobacterium.  However,  the  level  of  this bacterium in the gut did not regulate
adenoma formation in this mice model.
4. Subcellular localization of cell-signalling proteins b-catenin  and  PKC-z in the
mucosa tissue might be pivotal in inhibiting adenoma formation (IV,V). A low level of
nuclear b-catenin in the adenomas of 7-hydroxymatairesinol-fed mice and a high level
of PKC-z  in  the  mucosal  membrane  of  flaxseed-fed  mice  was  associated  with  a  low
tumour number and size in this animal model. The amount of COX-2 was shown to
increase during tumour growth, but the experimental diets did not affect the level of this
enzyme in the adenomas. Thus role of COX-2 in tumour progression remained unclear
5. The  colon  adenoma  number  was  affected  by  gender  such  that  male  Min  mice  had
twice the number of adenomas in the colon as female Min mice. This questions the
suitability of using colon adenoma number as an end-point marker.
Our knowledge of the relationship between lignans and the risks of various cancers in
human subjects and experimental animals has grown greatly during the past few years.
Although the results with this mouse model indicate that some lignans (e.g.
enterolactone, enterodiol and secoisolariciresinol) do not have an apparent
chemopreventive effect on colon carcinogenesis, these studies raised some new
questions which warrant further studies. Small differences in the chemical structure of
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pure lignans might be important with regard to lignan metabolism and
chemoprevention. Thus more detailed information is needed on lignans actions in vivo.
The oil component of the flaxseed mixture appeared to have a chemopreventive effect
on adenoma growth in Min mice. The effect of this a-linolenic acid-rich oil component
on colon tumourigenesis and possible mechanistic pathways (e.g. PKC-z and apoptosis)
should be verified and researched further. Exploiting such techniques as
immunohistochemistry may open new possibilities for examining the effects of dietary
components on subcellular localization of cell-signalling proteins, which seemed to be
pivotal for adenoma progression. The gender difference in lignan metabolism was
unexpected, and the reason for it remains unclear. The exact effects of gender on lignan
metabolism and perhaps on colon adenoma number are worthy of further studies.
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